Clinical Trials as Topic

• 

  Subject Areas on Research

  • "ALS reversals": demographics, disease characteristics, treatments, and co-morbidities. 
  • "I would really want to know that they had my back": Transgender women's perceptions of HIV cure-related research in the United States. 
  • "Opinions differ significantly": Early experiences with meta-analysis and the people who made it possible. 
  • 'A shot of his own': the acceptability of a male hormonal contraceptive in Indonesia. 
  • 'Smooth' inference for survival functions with arbitrarily censored data. 
  • 'Well, It's the Risk of the Unknown… Right?': A Qualitative Study of Perceived Risks and Benefits of HIV Cure Research in the United States. 
  • 'What do they know about it?' How the North Carolina public views cancer clinical trials: implications for primary care doctors. 
  • 10 questions about statins and stroke. 
  • 10 Years with ICH E10: Choice of Control Groups. 
  • 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVS key data elements and definitions for peripheral atherosclerotic vascular disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular Disease). 
  • 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). 
  • 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). 
  • 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). 
  • 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. 
  • 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. 
  • 21st century--Reproductive Medicine Network (RMN). 
  • 5-Fluorouracil in childhood solid tumors. 
  • 7 questions to ask when evaluating a noninferiority trial. 
  • A "best-in-class" systemic biomarker predictor of clinically relevant knee osteoarthritis structural and pain progression. 
  • A Bayesian approach on sample size calculation for comparing means. 
  • A Bayesian approach to subgroup identification. 
  • A Call for Change: Level of Statistical Significance. 
  • A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. 
  • A Critical Evaluation of the Representation of Black Patients With Heart Failure and Preserved Ejection Fraction in Clinical Trials: A Literature Review. 
  • A Guide to Reproducibility in Preclinical Research. 
  • A Proposal for Post Hoc Subgroup Analysis in Support of Regulatory Submission. 
  • A Review of Methods for Monitoring Adverse Events in Pediatric Psychopharmacology Clinical Trials. 
  • A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding? 
  • A Web-based compendium of clinical questions and medical evidence to educate internal medicine residents. 
  • A benefit of spinal manipulation as adjunctive therapy for acute low-back pain: a stratified controlled trial. 
  • A brief history of Wegener's granulomatosis: on limited, localized, and generalized forms of the disease: comment on the article by the Wegener's Granulomatosis Etanercept Trial Research Group. 
  • A call for collaboration: the evolving heart failure apprenticeship network. 
  • A centralized informatics infrastructure for the National Institute on Drug Abuse Clinical Trials Network. 
  • A comparative effectiveness review of parenting and trauma-focused interventions for children exposed to maltreatment. 
  • A comparison of phenelzine and imipramine in depressed inpatients. 
  • A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. 
  • A comparison of sublingual nifedipine versus nitroglycerin in the treatment of acute angina pectoris. 
  • A computational framework for the analysis of peptide microarray antibody binding data with application to HIV vaccine profiling. 
  • A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. 
  • A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer. 
  • A data-based approach to assessing clinical interventions in the setting of chronic disease. 
  • A design for the prospective evaluation of the efficacy and toxicity of antiepileptic drugs in adults. 
  • A direct comparison of presenting characteristics of depressed outpatients from primary vs. specialty care settings: preliminary findings from the STAR*D clinical trial. 
  • A directory for neonatal intensive care: potential for facilitating network-based research in neonatology. 
  • A double-blind comparison of bupropion and amitriptyline in depressed inpatients. 
  • A double-blind study comparing benoxaprofen, aspirin, and benoxaprofen plus aspirin in patients with rheumatoid arthritis. 
  • A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma. 
  • A double-blind, placebo-controlled trial of acitretin for the treatment of psoriasis. 
  • A general formulation for a one-sided group sequential design. 
  • A generalized estimating equation approach for modeling random length binary vector data. 
  • A global core outcome measurement set for snakebite clinical trials. 
  • A global rank end point for clinical trials in acute heart failure. 
  • A global ranking approach to end points in trials of mechanical circulatory support devices. 
  • A history of the concept of atypical depression. 
  • A hybrid Bayesian adaptive design for dose response trials. 
  • A leave-one-out cross-validation SAS macro for the identification of markers associated with survival. 
  • A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. 
  • A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A method of quantification for the evaluation of antiepileptic drug therapy. 
  • A model for harmonizing flow cytometry in clinical trials. 
  • A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections. 
  • A multicenter program for electronic health record screening for patients with heart failure with preserved ejection fraction: Lessons from the DELIVER-EHR initiative. 
  • A multicenter trial of antithymocyte globulin in aplastic anemia and related diseases. 
  • A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. 
  • A new design for randomized trials. 
  • A new model for catalyzing translational science: the early stage investigator mentored research scholar program in HIV vaccines. 
  • A new model for developing and executing culturally appropriate behavior modification clinical trials for African Americans. 
  • A new parameter in brain stem evoked response: component wave areas. 
  • A new wave in treatment of vascular occlusive disease: biodegradable stents--clinical experience and scientific principles. 
  • A note on sample size determination for bioequivalence studies with high-order crossover designs. 
  • A note on special articles on adaptive clinical trial designs. 
  • A note on statistical methods for assessing therapeutic equivalence. 
  • A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials. 
  • A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. 
  • A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. 
  • A phase I/II study of combined cisplatin and hyperthermia treatment for refractory malignancy. 
  • A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. 
  • A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. 
  • A population study of clinical trial accrual for women and minorities in neuro-oncology following the NIH Revitalization Act. 
  • A practical approach for comparing means of two groups without equal variance assumption. 
  • A practical approach for comparing means of two groups without equal variance assumption: H. Wang and S. Chow, Statistics in Medicine 2002; 21:3137-3151. 
  • A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. 
  • A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. 
  • A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. 
  • A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. 
  • A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. 
  • A randomized, controlled clinical trial of a geriatric consultation team. Compliance with recommendations. 
  • A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. 
  • A rationale for conducting parallel mechanistic studies in clinical trials of pharmacotherapy. 
  • A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma. 
  • A recursively interpreted data structure for representing clinical entities. 
  • A review of apixaban for stroke prevention in atrial fibrillation: insights from ARISTOTLE. 
  • A review of chemotherapy trials for malignant mesothelioma. 
  • A review of low-carbohydrate ketogenic diets. 
  • A robust method for estimating optimal treatment regimes. 
  • A semi-automated tool for treatment plan-quality evaluation and clinical trial quality assurance. 
  • A study of the correlation between endoscopic and histological diagnoses in gastroduodenitis. 
  • A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. 
  • A survey of monitoring practices in cancer clinical trials. 
  • A systematic review of morphea treatments and therapeutic algorithm. 
  • A systematic review of treatments for refractory depression in older people. 
  • A trial of outpatient chemotherapy for recurrent head and neck tumors. 
  • A trial of prophylactic cefamandole in extended gynecologic surgery. 
  • A year of successful cancer vaccines points to a path forward. 
  • AABIP Evidence-informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters. 
  • ACC/AHA 2013 methodology for developing clinical data standards: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. 
  • ACCF/AHA 2011 key data elements and definitions of a base cardiovascular vocabulary for electronic health records: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards. 
  • ACCF/AHA consensus conference report on professionalism and ethics. 
  • ACE inhibitors in hypertension: a US perspective. 
  • ALSUntangled #62: vitamin C. 
  • ALSUntangled 38: L-serine. 
  • ALSUntangled 44: curcumin. 
  • ALSUntangled 48: Perampanel (Fycompa). 
  • ALSUntangled No. 36: Accilion. 
  • ALSUntangled No. 37: Inosine. 
  • ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer. 
  • ASCPRO recommendations for the assessment of fatigue as an outcome in clinical trials. 
  • Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure: Results From the CABANA Trial. 
  • Academic medicine can transform health care through clinical research. 
  • Accelerated partial breast irradiation: caution and concern from an ASTRO task force. 
  • Accelerating stem cell trials for Alzheimer's disease. 
  • Access to patient-level data from GlaxoSmithKline clinical trials. 
  • Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. 
  • Acetylation phenotype, platelet monoamine oxidase inhibition, and the effectiveness of phenelzine in depression. 
  • Achieving the goals of effective, safe, and individualized cancer care. 
  • Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy. 
  • Action for Increasing Diversity, Market Access, and Capacity in Oncology Registration Trials-Is Africa the Answer? Report From a Satellite Session of the Accelerating Anti-Cancer Agent Development and Validation Workshop. 
  • Activation of tyrosine kinases in cancer. 
  • Activities and accomplishments of the cancer and leukemia group B genitourinary committee. 
  • Acupuncture as adjunctive therapy in assisted reproduction: remaining uncertainties. 
  • Acupuncture for neck disorders. 
  • Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. 
  • Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. 
  • Acute coronary syndromes and diabetes mellitus. 
  • Acute coronary syndromes in the elderly. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Acute ischemic stroke treatment in 2007. 
  • Acute myeloid leukemia clinical practice guidelines in oncology. 
  • Adapting to a Pandemic - Conducting Oncology Trials during the SARS-CoV-2 Pandemic. 
  • Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research. 
  • Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. 
  • Adaptive design in clinical research: issues, opportunities, and recommendations. 
  • Adaptive design methods in clinical trials - a review. 
  • Adaptive group sequential test for clinical trials with changing patient population. 
  • Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. 
  • Addressing the unit of analysis in medical care studies: a systematic review. 
  • Adenovirus vaccine immunotherapy targeting WT1-expressing tumors. 
  • Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. 
  • Adherence to Third European Cooperative Acute Stroke Study 3- to 4.5-hour exclusions and association with outcome: data from Get with the Guidelines-Stroke. 
  • Adjunctive adjuvant or neoadjuvant chemotherapy for locally advanced bladder cancer: a critical appraisal of the present status. 
  • Adjunctive erythromycin treatment for idiopathic preterm labor: results of a randomized, double-blinded, placebo-controlled trial. 
  • Adjusting for misclassification in a stratified biomarker clinical trial. 
  • Adjuvant chemotherapy in nonmetastatic osteosarcoma: a Southwest Oncology Group Study. 
  • Adjuvant therapy for colorectal cancer. 
  • Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. 
  • Adolescent and young adult cancer: a revolution in evolution? 
  • Advanced coronary artery disease: Appropriate end points for trials of novel therapies. 
  • Advanced pancreatic cancer: a phase I-II trial of cisplatin, high-dose cytarabine, and caffeine. 
  • Advanced topics in evidence-based urological oncology: using results of a subgroup analysis. 
  • Advances and challenges: dendritic cell vaccination strategies for glioblastoma. 
  • Advances in neurovascular treatments. 
  • Advances in pediatric neuroradiology: highlights of the recent medical literature. 
  • Advances in primary prevention and health services delivery. 
  • Advances in primary stroke prevention. 
  • Advancing neuromuscular ultrasound through research: Finding common sound. 
  • Adverse event load, onset, and maximum grade: A novel method of reporting adverse events in cancer clinical trials. 
  • Aerosolized ribavirin in the treatment of patients with respiratory syncytial virus disease. 
  • After fibrinolysis: is cardiac catheterization the answer? 
  • Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. 
  • Aggressive therapy of acute MI in the elderly. 
  • Aging and cancer. 
  • Alemtuzumab for the prevention and treatment of graft-versus-host disease. 
  • Alemtuzumab. 
  • Alopecia areata investigational assessment guidelines--Part II. National Alopecia Areata Foundation. 
  • Alphavirus replicon particles as candidate HIV vaccines. 
  • Alprazolam vs amitriptyline in depressions with reduced REM latencies. 
  • Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. 
  • Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. 
  • Alternative therapies for Clostridium difficile infections. 
  • American Association of Physicists in Medicine Task Group 263: Standardizing Nomenclatures in Radiation Oncology. 
  • American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). 
  • American College of Radiology Imaging Network: new national cooperative group for conducting clinical trials of medical imaging technologies. 
  • American College of Surgeons Oncology Group and the community surgeon. 
  • Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities. 
  • An Innovative Approach to Building an Effective and Efficient Pediatric Trial Network. 
  • An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. 
  • An accelerated pathway for targeted cancer therapies. 
  • An agenda for clinical research in geriatrics. 
  • An analysis of registered clinical trials in otolaryngology from 2007 to 2010: ClinicalTrials.gov. 
  • An approach to conducting epidemiologic research within cooperative clinical trials groups. 
  • An approach to the assessment of therapeutic drug interactions with fixed combination drug products. 
  • An assessment by the Statin Intolerance Panel: 2014 update. 
  • An assessment of cancer clinical trials vocabulary and IT infrastructure in the U.S. 
  • An early 'clinical trial' as a teaching exercise: the Book of Daniel 1.1-15 (1.1-20). 
  • An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. 
  • An evaluation of the relationship between the quality of prophylactic cranial radiotherapy in childhood acute leukemia and institutional experience: a Quality Assurance Review Center-Pediatric Oncology Group study. 
  • An evolutionary framework for treating pediatric sarcomas. 
  • An experiment to change detection and management of mental morbidity in primary care. 
  • An outpatient evaluation of phenelzine and imipramine. 
  • An update on acute myocardial infarction from recent clinical trials. 
  • An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. 
  • Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. 
  • Analysis of combined data from heterogeneous study designs: an applied example from the patient navigation research program. 
  • Analysis of dermatologic events in patients with cancer treated with lapatinib. 
  • Analysis of professional competencies for the clinical research data management profession: implications for training and professional certification. 
  • Analysis strategies for adaptive designs with multiple endpoints. 
  • Anastomotic leaks after laparoscopic gastric bypass. 
  • Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. 
  • Anemia and cancer in older persons. 
  • Anesthetic neuroprotection: antecedents and an appraisal of preclinical and clinical data quality. 
  • Angiogenic therapy for coronary artery and peripheral arterial disease. 
  • Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. 
  • Angiographic diagnosis and endovascular management of nonvariceal gastrointestinal hemorrhage. 
  • Animal, vegetable, or ... clinical trial? 
  • Anthracyclines in the treatment of early-stage breast cancer: ally or adversary? 
  • Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. 
  • Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis. 
  • Antianginal effects of intravenous nitroglycerin over 24 hours. 
  • Antibiotics for acute maxillary sinusitis in adults. 
  • Antibiotics for acute maxillary sinusitis. 
  • Antibiotics for acute maxillary sinusitis. 
  • Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved. 
  • Anticoagulant therapy for percutaneous coronary intervention. 
  • Anticoagulant therapy in unstable angina. 
  • Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). 
  • Antidepressant drug therapy in psychotic depression. 
  • Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. 
  • Antifibrinolytic Therapy for Cardiac Surgery: An Update. 
  • Antihypertensive effectiveness of very low doses of hydrochlorothiazide: results of the PHICOG Trial. 
  • Antiphospholipid Syndrome Clinical Research Task Force report. 
  • Antiplatelet therapy: Clopidogrel-PPI interaction, an ongoing controversy. 
  • Antithrombotic Therapy in Peripheral Artery Disease: Generating and Translating Evidence Into Practice. 
  • Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. 
  • Antithrombotic therapy in peripheral artery disease: A review of the EUCLID trial results and current ongoing trials. 
  • Antithymocyte globulin: a realistic approach to therapy for severe aplastic anemia. 
  • Aortic counterpulsation in acute myocardial infarction: physiologically important but does the patient benefit? 
  • Apixaban: an emerging oral factor Xa inhibitor. 
  • Application of antimicrobial stewardship to optimise management of community acquired pneumonia. 
  • Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. 
  • Applications of TMS to therapy in psychiatry. 
  • Applications of the bayesian prior information to evaluation of equivalence of similar biological medicinal products. 
  • Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis. 
  • Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. 
  • Approaches for optimal sequential decision analysis in clinical trials. 
  • Approaches to HIV vaccine design. 
  • Approaching Regulatory Approval of Cardiovascular Regenerative Therapy. 
  • Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. 
  • Appropriate use criteria: past, present, future. 
  • Are current clinical trials in diabetes addressing important issues in diabetes care? 
  • Are uncontrolled clinical studies ever justified? 
  • Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. 
  • Arrhythmias in Female Patients: Incidence, Presentation and Management. 
  • Arti Hurria, M.D.: A tribute to her shining legacy in the Alliance for Clinical Trials in Oncology. 
  • Articular fractures. 
  • Aspirin and clopidogrel resistance: consideration and management. 
  • Aspirin in cardiovascular disorders. What is the optimum dose? 
  • Assessing Psychological Toxicity and Patient-Reported Distress as the Sixth Vital Sign in Cancer Care and Clinical Trials. 
  • Assessing anxious features in depressed outpatients. 
  • Assessing clinical and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. 
  • Assessing intra, inter and total agreement with replicated readings. 
  • Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. 
  • Assessment and treatment of depression in patients with cardiovascular disease: National Heart, Lung, and Blood Institute Working Group Report. 
  • Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017. 
  • Assessment of pain in herpes zoster: lessons learned from antiviral trials. 
  • Association between cyclosporin neurotoxicity and hypomagnesaemia. 
  • Association between funding sources and the scope and outcomes of cardiovascular clinical trials: A systematic review. 
  • Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease: The EUCLID Trial. 
  • Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. 
  • Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. 
  • Atherosclerosis: Recent trials, new targets and future directions. 
  • Attitudes toward clinical trials among patients with sickle cell disease. 
  • Augmented Beta rectangular regression models: A Bayesian perspective. 
  • Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. 
  • Automated recognition of spontaneous facial expression in individuals with autism spectrum disorder: parsing response variability. 
  • B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review. 
  • Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. 
  • Banff 2011 Meeting report: new concepts in antibody-mediated rejection. 
  • Barbiturate-induced coma to protect against cerebral ischemia and increased intracranial pressure. 
  • Barriers to Change in the Informed Consent Process: A Systematic Literature Review. 
  • Barriers to clinical trial participation by older women with breast cancer. 
  • Barriers to the participation of African-American patients with cancer in clinical trials: a pilot study. 
  • Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum. 
  • Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). 
  • Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial. 
  • Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. 
  • Bayesian hierarchical functional data analysis via contaminated informative priors. 
  • Bayesian hierarchical model for multiple repeated measures and survival data: an application to Parkinson's disease. 
  • Bayesian inference for smoking cessation with a latent cure state. 
  • Behavioral approaches to secondary prevention of coronary heart disease. 
  • Behavioral headache treatment: history, review of the empirical literature, and methodological critique. 
  • Belimumab use during pregnancy: a summary of birth defects and pregnancy loss from belimumab clinical trials, a pregnancy registry and postmarketing reports. 
  • Beneficial effects of pinacidil on blood lipids: comparisons with prazosin and placebo in patients with hypertension. Pinacidil-Prazosin and Pinacidil-Placebo Research Groups, Lilly Research Laboratories. 
  • Benefits of Direct-Acting Antivirals for Hepatitis C. 
  • Benefits, challenges and obstacles of adaptive clinical trial designs. 
  • Best supportive care in clinical trials: review of the inconsistency in control arm design. 
  • Betaxolol and timolol. A comparison of efficacy and side effects. 
  • Better outcomes for patients treated at hospitals that participate in clinical trials. 
  • Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. 
  • Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. 
  • Beyond 5-fluorouracil: the emerging role of newer chemotherapeutics and targeted agents with radiation therapy. 
  • Beyond minerals and parathyroid hormone: role of active vitamin D in end-stage renal disease. 
  • Beyond privacy: A deeper understanding of the internet is required to protect digitized trial participants. 
  • Biological and clinical aspects of hyperthermia in cancer therapy. 
  • Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. 
  • Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues. 
  • Biomarkers and correlative endpoints for immunotherapy trials. 
  • Biomarkers and surrogate endpoints in glaucoma clinical trials. 
  • Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation. 
  • Biomarkers as surrogate end points in heart failure trials. 
  • Biomarkers for Risk Stratification in Patients With Previously Untreated Follicular Lymphoma Receiving Anti-CD20-based Biological Therapy. 
  • Biomarkers in cardiovascular clinical trials: past, present, future. 
  • Biomedical imaging symposium: visualizing the future of biology and medicine. 
  • Biosimilars: are they ready for primetime in the United States? 
  • Bipolar disorder and crossover design. 
  • Bladder cancer. Clinical guidelines in oncology. 
  • Bladder cancer: chemohyperthermia for bladder cancer--clinically effective? 
  • Bleeding after antithrombotic therapy in patients with acute ischemic heart disease: is it the drugs or how we use them? 
  • Blood Pressure and Arterial Load After Transcatheter Aortic Valve Replacement for Aortic Stenosis. 
  • Blood Substitutes and Oxygen Therapeutics: A Review. 
  • Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. 
  • Bolus fibrinolysis: risk, benefit, and opportunities. 
  • Bone marrow transplantation for sickle cell disease. 
  • Brain immunology and immunotherapy in brain tumours. 
  • Breakout IV. Health professional concerns in the practice setting. 
  • Breast implant-associated anaplastic large cell lymphoma: sensitivity, specificity, and findings of imaging studies in 44 patients. 
  • Bridging studies in clinical development. 
  • Bridging the gap between clinical trials of antiplatelet therapies and applications among elderly patients. 
  • Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? 
  • Bucindolol: new hopes from reviewing past data. 
  • Building gold standard corpora for medical natural language processing tasks. 
  • Bumps and bridges on the road to responsible sharing of clinical trial data. 
  • Bupropion dosing recommendations. 
  • Bupropion sustained release: a therapeutic overview. 
  • CAR T cells and checkpoint inhibition for the treatment of glioblastoma. 
  • CD19: a promising B cell target for rheumatoid arthritis. 
  • CDK4/6 inhibitors in breast cancer. 
  • CNS prophylaxis in acute lymphoblastic leukemia: comparison of two methods a Southwest Oncology Group study. 
  • COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. 
  • COVID-19 interventional trials: Analysis of data sharing intentions during a time of pandemic. 
  • COVID-19 trials: declarations of data sharing intentions at trial registration and at publication. 
  • Caffeine effects on cardiovascular and neuroendocrine responses to acute psychosocial stress and their relationship to level of habitual caffeine consumption. 
  • Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. 
  • Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. 
  • Can one assess whether missing data are missing at random in medical studies? 
  • Can surgeons improve survival in stage IV melanoma? 
  • Can underpowered clinical trials be justified? 
  • Canadian Association for Immunization Research and Evaluation (CAIRE) guidelines for industry-sponsored clinical trial and epidemiology contract research. 
  • Cancer and leukemia group B gastrointestinal cancer committee. 
  • Cancer chemotherapeutic response and intravenous hyperalimentaion. 
  • Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. 
  • Cancer vaccines in colon and rectal cancer over the last decade: lessons learned and future directions. 
  • Cancer- and treatment-related anemia. 
  • Capacity Building in a New Clinical Trials Network through Inter-Network Collaboration. 
  • Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. 
  • Cardiac MRI Endpoints in Myocardial Infarction Experimental and Clinical Trials: JACC Scientific Expert Panel. 
  • Cardiac arrhythmias following anesthesia induction in infantile-onset Pompe disease: a case series. 
  • Cardiac markers in the assessment of acute coronary syndromes. 
  • Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends. 
  • Cardiopulmonary Impact of Particulate Air Pollution in High-Risk Populations: JACC State-of-the-Art Review. 
  • Cardiorenal Interactions. 
  • Cardiorenal syndrome clinical trial end points. 
  • Cardiovascular Outcome Trial Update in Diabetes: New Evidence, Remaining Questions. 
  • Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer. 
  • Cardiovascular disease on a global scale: defining the path forward for research and practice. 
  • Cardiovascular drug development: is it dead or just hibernating? 
  • Cardiovascular magnetic resonance in patients with myocardial infarction: current and emerging applications. 
  • Cardiovascular responses during upright and semi-recumbent cycle ergometry testing. 
  • Catastrophic Disruptions in Clinical Trials. 
  • Catheter ablation of ventricular tachycardia: Lessons learned from past clinical trials and implications for future clinical trials. 
  • Cefoperazone as a prophylactic agent in abdominal hysterectomy. 
  • Ceftaroline applications for therapy in the United States. 
  • Ceftaroline for complicated skin and skin-structure infections. 
  • Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. 
  • Cell therapy for diverse central nervous system disorders: inherited metabolic diseases and autism. 
  • Cell-based interventions for neurologic conditions: ethical challenges for early human trials. 
  • Cell-internalization SELEX: method for identifying cell-internalizing RNA aptamers for delivering siRNAs to target cells. 
  • Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials. 
  • Certolizumab pegol. 
  • Cervical priming prior to first-trimester suction abortion with a single 15-methyl-prostaglandin F2 alpha vaginal suppository. 
  • Challenges in enrollment of minority, pediatric, and geriatric patients in emergency and acute care clinical research. 
  • Challenges in the pursuit of immune tolerance. 
  • Challenges with Novel Clinical Trial Designs: Master Protocols. 
  • Changes in criteria for tumor response. 
  • Changes in hemostasis after parenteral magnesium in myocardial ischemia-reperfusion: from animal studies to clinical trials. 
  • Changes in willingness to participate in HIV vaccine trials among HIV-negative injection drug users. 
  • Changing multidisciplinary cancer treatment through ACOSOG trials. 
  • Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. 
  • Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. 
  • Characteristics of clinical trials evaluating cardiovascular therapies for Coronavirus Disease 2019 Registered on ClinicalTrials.gov: a cross sectional analysis. 
  • Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. 
  • Characteristics of insured and noninsured outpatients with depression in STAR(*)D. 
  • Characteristics of oncology clinical trials: insights from a systematic analysis of ClinicalTrials.gov. 
  • Characteristics of pediatric cardiovascular clinical trials registered on ClinicalTrials.gov. 
  • Charting the course of clinical research: from an inspired past to a promising future. 
  • Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading. 
  • Checkpoint inhibitors in hematological malignancies. 
  • Chemotherapy dose intensity and quality cancer care. 
  • Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies. 
  • Chemotherapy in malignant pleural mesothelioma. A review. 
  • Chemotherapy in soft-tissue sarcoma: where do we go from here? 
  • Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology. 
  • China-United States Research Collaborations in Antimicrobial Resistance. 
  • Cholesterol rethink for high-risk patients. 
  • Choosing Core Outcomes for Use in Clinical Trials in Ophthalmology: Perspectives from Three Ophthalmology Outcomes Working Groups. 
  • Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. 
  • Chronic Stroke Outcome Measures for Motor Function Intervention Trials: Expert Panel Recommendations. 
  • Chronic Thromboembolic Pulmonary Hypertension: Evolving Therapeutic Approaches for Operable and Inoperable Disease. 
  • Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study. 
  • Chronic stable angina monotherapy. Nifedipine versus propranolol. 
  • Cimetidine for stress-ulcer prophylaxis. 
  • Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer. 
  • Circulating long chain acylcarnitines and outcomes in diabetic heart failure: an HF-ACTION clinical trial substudy. 
  • Circulatory effects of fenfluramine in obese hypertensive patients. 
  • Cisplatin, BCNU, cyclophosphamide, and prednisone in multiple myeloma. 
  • Clarifying the Meaning of Clinically Meaningful Benefit in Clinical Research: Noticeable Change vs Valuable Change. 
  • Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. 
  • Clinical Quantification of Myocardial Blood Flow Using PET: Joint Position Paper of the SNMMI Cardiovascular Council and the ASNC. 
  • Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles: A Consensus Document From the Mitral Valve Academic Research Consortium. 
  • Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium. 
  • Clinical Trial Design in Juvenile Idiopathic Arthritis. 
  • Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice. 
  • Clinical Trials Versus Clinical Practice: When Evidence and Practice Diverge--Should Nondiabetic Patients With 3-Vessel Disease and Stable Ischemic Heart Disease Be Preferentially Treated With CABG? 
  • Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage. 
  • Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. 
  • Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. 
  • Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. 
  • Clinical applications for biomarkers of acute and chronic graft-versus-host disease. 
  • Clinical applications of a peptide-based vaccine for glioblastoma. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical assessment of atherosclerotic lesions: emerging from angiographic shadows. 
  • Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. 
  • Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). 
  • Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. 
  • Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. 
  • Clinical end points in coronary stent trials: a case for standardized definitions. 
  • Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. 
  • Clinical implications of pulmonary hypertension in mitral stenosis. 
  • Clinical issues in considering vagus nerve stimulation for treatment-resistant depression. 
  • Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. 
  • Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. 
  • Clinical outcomes according to time to treatment. 
  • Clinical outcomes after implantation of a centrifugal flow left ventricular assist device and concurrent cardiac valve procedures. 
  • Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. 
  • Clinical profiles in acute heart failure: an urgent need for a new approach. 
  • Clinical reasoning and prevention of cardiovascular disease. 
  • Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. 
  • Clinical research in primary stroke prevention: needs, opportunities, and challenges. 
  • Clinical research. 
  • Clinical roundtable monograph: new and emerging treatments for advanced prostate cancer. 
  • Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. 
  • Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation. 
  • Clinical stroke trials: guarding against bias. 
  • Clinical study evaluating efficacy of praziquantel in clonorchiasis. 
  • Clinical trial Data and Safety Monitoring Boards. The search for a constitution. 
  • Clinical trial accrual in older cancer patients: The most important steps are the first ones. 
  • Clinical trial design in neonatal pharmacology: effect of center differences, with lessons from the Pediatric Oncology Cooperative Research experience. 
  • Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles: A consensus document from the mitral valve academic research consortium. 
  • Clinical trial end points for high-grade glioma: the evolving landscape. 
  • Clinical trial issues in weight-loss therapy. 
  • Clinical trial recruitment challenges with older adults with cancer. 
  • Clinical trial registration in physical therapy journals: Recommendations from the International Society of Physiotherapy Journal Editors. 
  • Clinical trial registration in physical therapy journals: recommendations from the International Society of Physiotherapy Journal Editors. 
  • Clinical trial registration in physiotherapy journals: recommendations from the International Society of Physiotherapy Journal Editors. 
  • Clinical trial registration in physiotherapy journals: recommendations from the International Society of Physiotherapy Journal Editors. 
  • Clinical trial registration in physiotherapy journals: recommendations from the International Society of Physiotherapy Journal Editors. 
  • Clinical trial--derived risk model may not generalize to real-world patients with acute coronary syndrome. 
  • Clinical trials and medical care: defining the therapeutic misconception. 
  • Clinical trials and registries in cardiovascular disease: competitive or complementary? 
  • Clinical trials data collection: when less is more. 
  • Clinical trials in Japan and the United States. 
  • Clinical trials in acute decompensated heart failure--over 50 years of research. 
  • Clinical trials in children with Down syndrome: issues from a cognitive research perspective. 
  • Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. 
  • Clinical trials in mechanical circulatory support. 
  • Clinical trials in pediatric rheumatology: comment on the editorial by Lehman. 
  • Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. 
  • Clinical trials in progressive neurological diseases. Recruitment, enrollment, retention and compliance. 
  • Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. 
  • Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? 
  • Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative. 
  • Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. 
  • Clinical trials. How should they be designed? 
  • Clinical trials: to terminate or not to terminate. The VA Cooperative Studies Group on AIDS. 
  • Clinical trials: where are we now? 
  • Clinical trials:randomization before consent. 
  • ClinicalTrials.gov reporting: strategies for success at an academic health center. 
  • Clobetasol propionate versus fluocinonide creams in psoriasis and eczema. 
  • Clonidine and chlorthalidone (combipres) in hypertension. 
  • Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. 
  • Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. 
  • Closing the Evidence Gap in Interstitial Lung Disease. The Promise of Real-World Data. 
  • Coagulation markers and outcomes in acute coronary syndromes. 
  • Coefficients of agreement for fixed observers. 
  • Cognition in schizophrenia: summary Nice Consultation Meeting 2012. 
  • Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. 
  • Combat Wound Initiative program. 
  • Combating Structural Inequities - Diversity, Equity, and Inclusion in Clinical and Translational Research. 
  • Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force. 
  • Combination chemotherapy for osteosarcoma. 
  • Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. 
  • Combination hormonal therapy: a reassessment within advanced prostate cancer. 
  • Combinations of Bevacizumab With Cancer Immunotherapy. 
  • Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. 
  • Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. 
  • Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index. 
  • Combining structure and function to evaluate glaucomatous progression: implications for the design of clinical trials. 
  • Commentary: Per capita payments in clinical trials: reasonable costs versus bounty hunting. 
  • Community based trials and informed consent in rural north India. 
  • Community impact of anticoagulation services: rationale and design of the Managing Anticoagulation Services Trial (MAST). 
  • Community recruitment process by race, gender, and SES gradient: lessons learned from the Community Health and Stress Evaluation (CHASE) Study experience. 
  • Comorbidity in older adults with cancer. 
  • Comparative effectiveness research and demonstrating clinical utility for molecular diagnostic tests. 
  • Comparative effectiveness research: moving medical oncology forward. 
  • Comparative efficacy of "specific" potassium citrate therapy versus conservative management in nephrolithiasis of mild to moderate severity. 
  • Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents with depression study. 
  • Comparative trials of chemotherapy and bone marrow transplantation in acute nonlymphocytic leukemia. 
  • Comparing classifications of death in the Mode Selection Trial: agreement and disagreement among site investigators and a clinical events committee. 
  • Comparing radical prostatectomy and brachytherapy for localized prostate cancer. 
  • Comparing recruitment strategies to engage hard-to-reach men who have sex with men living with HIV with unsuppressed viral loads in four US cities: Results from HPTN 078. 
  • Comparing the Benefit of Novel Therapies Across Clinical Trials: Insights From the VICTORIA Trial. 
  • Comparison of 2D reconstructions of surgically excised subfoveal choroidal neovascularization with fluorescein angiographic features: SST report No. 15. 
  • Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). 
  • Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. 
  • Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis. 
  • Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. 
  • Comparison of low-dose cinoxacin therapy and placebo in the prevention of recurrent urinary tract infections. 
  • Comparison of nifedipine alone with propranolol alone for stable angina pectoris including hemodynamics at rest and during exercise. 
  • Comparison of optical coherence tomography in diabetic macular edema, with and without reading center manual grading from a clinical trials perspective. 
  • Comparison of outcomes for African Americans, Hispanics, and Non-Hispanic Whites in the CATIE study. 
  • Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery. 
  • Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial. 
  • Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. 
  • Compassionate use of stem cells for ALS: popovers and hot air. 
  • Complex immune correlates of protection in HIV-1 vaccine efficacy trials. 
  • Complexity of Delivering Precision Medicine: Opportunities and Challenges. 
  • Compliance with results reporting at ClinicalTrials.gov. 
  • Compliance with results reporting at ClinicalTrials.gov. 
  • Compliance with therapeutic guidelines in Radiation Therapy Oncology Group prospective gastrointestinal clinical trials. 
  • Composite End Points in Clinical Research: A Time for Reappraisal. 
  • Comprehensive lifestyle modification and blood pressure control: a review of the PREMIER trial. 
  • Computational Causal Modeling of the Dynamic Biomarker Cascade in Alzheimer's Disease. 
  • Con: Methylprednisolone is not indicated for patients during cardiopulmonary bypass. 
  • Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel. 
  • Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials. 
  • Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). 
  • Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. 
  • Conducting research with racial/ethnic minorities: methodological lessons from the NIDA Clinical Trials Network. 
  • Conference on advances in AIDS vaccine development--1993. Summary: correlates of HIV Immunity Working Group. 
  • Confidentiality: more than a linkage file and a locked drawer. 
  • Conflict of interest disclosure in off-label oncology clinical trials. 
  • Conflicts of Interest and Outcomes of Cardiovascular Trials. 
  • Congressional update: Report from the biomedical imaging program of the National Cancer Institute. Research recommendations from a lung cancer screening workshop. 
  • Consensus on Language for Advance Informed Consent in Health Care-Associated Pneumonia Clinical Trials Using a Delphi Process. 
  • Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. 
  • Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. 
  • Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. 
  • Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. 
  • Consensus-based standards for best supportive care in clinical trials in advanced cancer. 
  • Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. 
  • Conservative management of acute coronary syndrome: cheaper and better for you? 
  • Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults. 
  • Considerations in reporting palliative care clinical trials: standardizing information reported and authorship practices. 
  • Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. 
  • Contemporary cardiovascular device clinical trials (trends and patterns 2001 to 2012). 
  • Continuous peripheral nerve blocks: fewer excuses. 
  • Continuous-infusion diaziquone in acute myeloid leukemia: a Southeastern Cancer Study Group trial. 
  • Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. 
  • Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. 
  • Controlling symptoms in elderly lung cancer patients. 
  • Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. 
  • Conversation in cardiology: Is there a need for clinical trials for the nonhyperemic pressure ratios? 
  • Cord blood for brain injury. 
  • Core lab analysis of baseline echocardiographic studies in the STICH trial and recommendation for use of echocardiography in future clinical trials. 
  • Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis. 
  • Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. 
  • Coronary artery stents. American College of Cardiology. 
  • Coronary intervention and glycoprotein IIb/IIIa integrin blockade. 
  • Correlates of HIV vaccine trial participation: an Indian perspective. 
  • Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. 
  • Correlation of epidermal plasminogen activator activity with disease activity in psoriasis. 
  • Correlation of hip fracture with other fracture types: Toward a rational composite hip fracture endpoint. 
  • Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers? 
  • Creation of a Multicenter Pediatric Inpatient Data Repository Derived from Electronic Health Records. 
  • Criteria and definitions for response and relapse in children with brain tumors. 
  • Criteria supporting the study of drugs in the newborn. 
  • Criterion-related validity of a diarrhea questionnaire in HIV-infected patients. 
  • Cross-trial comparisons in reviews: proceed with caution. 
  • Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells. 
  • Current management of acute lymphoblastic leukemia in adults. 
  • Current perspectives on locally advanced pancreatic cancer. 
  • Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 
  • Current status of clinical trials in head and neck cancer 2014. 
  • Current status of dendritic cell immunotherapy of malignancies. 
  • Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference. 
  • Cyclophosphamide therapy of medulloblastoma: from the laboratory to the clinic and back again (and again and again). 
  • Cytoprotection for radiation-associated normal tissue injury. 
  • Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions. 
  • Data Sharing and Embedded Research. 
  • Data Sharing at a Crossroads. 
  • Data and safety monitoring boards: academic credit where credit is due? 
  • Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations. 
  • Data monitoring and large apparent treatment effects. 
  • Davidson Trauma Scale (DTS): normative scores in the general population and effect sizes in placebo-controlled SSRI trials. 
  • Death: The Simple Clinical Trial Endpoint. 
  • Debate of adjunctive pharmacology for percutaneous coronary intervention: anticoagulation and clopidogrel are not (always) enough. 
  • Decade-Long Profile of Imaging Biomarker Use in Ophthalmic Clinical Trials. 
  • Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. 
  • Deficient Mismatch Repair and the Role of Immunotherapy in Metastatic Colorectal Cancer. 
  • Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. 
  • Defining Staged Procedures for Percutaneous Coronary Intervention Trials: A Guidance Document. 
  • Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. 
  • Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. 
  • Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. 
  • Defining the learning curve for successful staging with sentinel lymph node biopsy for endometrial cancer among surgeons at an academic institution. 
  • Defining the path ahead for NOAC use in the pediatric population: A Cardiac Safety Research Consortium Think Tank. 
  • Definition and Prioritization of Data Elements for Cohort Studies and Clinical Trials on Patients with Unruptured Intracranial Aneurysms: Proposal of a Multidisciplinary Research Group. 
  • Definitions and Clinical Trial Design Principles for Coronary Artery Chronic Total Occlusion Therapies: CTO-ARC Consensus Recommendations. 
  • Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access. 
  • Delivering clinical trials at home: protocol, design and implementation of a direct-to-family paediatric lupus trial. 
  • Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. 
  • Dendritic cell gene therapy. 
  • Dendritic cell vaccines. 
  • Dendritic cell-based immunization for cancer therapy. 
  • Dendritic cell-based immunotherapy. 
  • Denosumab for the treatment of osteoporosis. 
  • Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. 
  • Department of Health and Human Services National Institutes of Health Recombinant DNA Advisory Committee. Minutes of meeting March 8-10, 2000. 
  • Depletion of circulating progenitor cells precedes overt diabetes: a substudy from the VA enhanced fitness trial. 
  • Depressed outpatients treated with cognitive therapy or pharmacotherapy. A one-year follow-up. 
  • Depression and coronary heart disease: association and implications for treatment. 
  • Depression and ischemic heart disease: what have we learned from clinical trials? 
  • Depression and ischemic heart disease: what have we learned so far and what must we do in the future? 
  • Depression, coronary events, platelet inhibition, and serotonin reuptake inhibitors. 
  • Design Elements and Enrollment Patterns of Contemporary Trials in Heart Failure With Preserved Ejection Fraction: A Systematic Review. 
  • Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment. 
  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. 
  • Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients. 
  • Designing clinical trials for paroxysmal atrial tachycardia and other paroxysmal arrhythmias. 
  • Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. 
  • Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). 
  • Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. 
  • Detection and management of mental health problems of older patients by primary care providers. 
  • Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era. 
  • Determinants of successful glycemic control among participants in the BARI 2D trial: a post-hoc analysis. 
  • Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapies. 
  • Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. 
  • Determining the efficacy of antiplatelet therapies for the individual: lessons from clinical trials. 
  • Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. 
  • Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease. 
  • Developing an HIV vaccine. 
  • Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. 
  • Developing and Implementing Performance Outcome Assessments: Evidentiary, Methodologic, and Operational Considerations. 
  • Developing drugs for treatment of atopic dermatitis in children (≥3 months to <18 years of age): Draft guidance for industry. 
  • Developing the evidence base for palliative care: formation of the Palliative Care Research Cooperative and its first trial. 
  • Developing therapies for heart failure with preserved ejection fraction: current state and future directions. 
  • Development and Course of Scars in the Comparison of Age-Related Macular Degeneration Treatments Trials. 
  • Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease. 
  • Development and validation of a risk score for predicting pericardial effusion in patients undergoing leadless pacemaker implantation: experience with the Micra transcatheter pacemaker. 
  • Development of DX-9065a, a novel direct factor Xa antagonist, in cardiovascular disease. 
  • Development of a Retinopathy of Prematurity Activity Scale and Clinical Outcome Measures for Use in Clinical Trials. 
  • Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. 
  • Development of a protocol for allogeneic marrow transplantation for severe systemic sclerosis: paradigm for autoimmune disease. 
  • Development of a vaccine for the prevention of AIDS, a critical appraisal. 
  • Development of novel targeted therapies in the treatment of malignant glioma. 
  • Developmental pharmacogenomics. 
  • Device profile of the XVision-spine (XVS) augmented-reality surgical navigation system: overview of its safety and efficacy. 
  • Device therapy in heart failure patients with chronic kidney disease. 
  • Dexamethasone suppression test status does not predict differential response to nortriptyline versus amitriptyline. 
  • Diabetic kidney disease: a report from an ADA Consensus Conference. 
  • Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. 
  • Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment. 
  • Differences in Toxicity and Outcomes in Clinical Trial Participants From Minority Populations. 
  • Differences in the approval process for interventional devices in Europe and USA: IN MEDIO STAT VIRTUS. 
  • Differential effects of cognitive therapy and pharmacotherapy on depressive symptoms. 
  • Differential survival with Alzheimer disease. 
  • Differentiation of hemodynamic, humoral and metabolic responses to beta 1- and beta 2-adrenergic stimulation in man using atenolol and propranolol. 
  • Difficulties in applying clinical trial information to the practice setting: case of a high-cost drug. 
  • Digital pathology in nephrology clinical trials, research, and pathology practice. 
  • Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. 
  • Direct oral anticoagulants: a review on the current role and scope of reversal agents. 
  • Direct thrombin inhibitors. 
  • Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can't Do? 
  • Discovery and development of lamotrigine for bipolar disorder: a story of serendipity, clinical observations, risk taking, and persistence. 
  • Disease due to enterotoxigenic Escherichia coli in Bangladeshi adults: clinical aspects and a controlled trial of tetracycline. 
  • Disparities in older adult accrual to cancer trials: Analysis from the alliance for clinical trials in oncology (A151736). 
  • Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia. 
  • Disrupting nicotine reinforcement: from cigarette to brain. 
  • Distal radius fractures in the elderly. 
  • Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. 
  • Diversity and transparency in gynecologic oncology clinical trials. 
  • Diversity of Enrollment in Prostate Cancer Clinical Trials: Current Status and Future Directions. 
  • Do Women and Men Respond Similarly to Therapies in Contemporary Heart Failure Clinical Trials? 
  • Do patients participating in clinical trials want to know study results? 
  • Do we need to adjudicate major clinical events? 
  • Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier. 
  • Does Meditation Enhance Cognition and Brain Longevity? 
  • Does diffusion-weighted imaging represent the ischemic core? An evidence-based systematic review. 
  • Does information from ClinicalTrials.gov increase transparency and reduce bias? Results from a five-report case series. 
  • Does informed consent to research require comprehension? 
  • Does study subject diversity influence cardiology research site performance?: Insights from 2 U.S. National Coronary Stent Registries. 
  • Domestic violence among adolescents in HIV prevention research in Tanzania: participant experiences and measurement issues. 
  • Don't ask, don't tell? Revealing placebo responses to research participants and patients. 
  • Donepezil for Down's syndrome. 
  • Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. 
  • Dosing in neonates: special considerations in physiology and trial design. 
  • Double-blind placebo controlled trial of erythromycin for treatment of Campylobacter enteritis. 
  • Double-blind randomized comparison of intravenous tocainide versus lidocaine in the treatment of chronic ventricular arrhythmias. 
  • Double-blind, placebo-controlled trial of twice-daily nifedipine as a step-2 agent in mild essential hypertension. 
  • Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression. 
  • Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? 
  • Drug Trials in Status Epilepticus: Current Evidence and Future Concepts. 
  • Drug and alcohol trajectories among adults with schizophrenia: data from the CATIE study. 
  • Drug discovery and development for ageing: opportunities and challenges. 
  • Drugs for percutaneous coronary interventions. 
  • Duration of Pediatric Clinical Trials Submitted to the US Food and Drug Administration. 
  • Dysfunctional attitudes in depressed patients before and after clinical treatment and in normal control subjects. 
  • Dyskinesias associated with lithium therapy in parkinsonism. 
  • ECG subanalyses in clinical trials: an investigator's perspective. 
  • EGFRvIII-targeted vaccination therapy of malignant glioma. 
  • EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. 
  • Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptor. 
  • Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. 
  • Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. 
  • Ebola clinical trials: Five lessons learned and a way forward. 
  • Echinocandins: addressing outstanding questions surrounding treatment of invasive fungal infections. 
  • Echocardiographic imaging in clinical trials: American Society of Echocardiography Standards for echocardiography core laboratories: endorsed by the American College of Cardiology Foundation. 
  • Echocardiographic imaging of procedural complications during balloon-expandable transcatheter aortic valve replacement. 
  • Economic and cost-effectiveness in evaluating the value of cardiovascular therapies. The impact of the cost-effectiveness study of GUSTO-1 on decision making with regard to fibrinolytic therapy. 
  • Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation. 
  • Economic return of clinical trials performed under the pediatric exclusivity program. 
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Use of abciximab: comparative economic data. 
  • Editorial: Licensing and Use of New Therapies in MS: Where Are We Going? 
  • Effect of a geriatric consultation team on functional status of elderly hospitalized patients. A randomized, controlled clinical trial. 
  • Effect of aerobic training on the host systemic milieu in patients with solid tumours: an exploratory correlative study. 
  • Effect of bromocriptine on affect and libido in hyperprolactinemia. 
  • Effect of dialysate composition on the lipid response to L-carnitine supplementation. 
  • Effect of dropouts on sample size estimates for test on trends across repeated measurements. 
  • Effect of parenteral amino acid supplementation in alcoholic hepatitis. 
  • Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator. 
  • Effect of socioeconomic status as measured by education level on survival in breast cancer clinical trials. 
  • Effect of ultraviolet light on topical minoxidil-induced hair growth in advanced male pattern baldness. 
  • Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid. 
  • Effects of alpha- and beta-adrenergic antagonists on plasma apolipoproteins and forearm blood flow in patients with mild hypertension. 
  • Effects of beta 1-selective and nonselective beta-adrenoceptor blockade during exercise conditioning in healthy adults. 
  • Effects of continuous or discontinuous maintenance therapy on subsequent remission maintenance in childhood leukemia. 
  • Effects of disclosing financial interests on attitudes toward clinical research. 
  • Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups. 
  • Effects of repetitive transcranial magnetic stimulation on motor symptoms in Parkinson disease: a systematic review and meta-analysis. 
  • Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. 
  • Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program. 
  • Efficacy and effectiveness approaches in behavioral treatment trials. 
  • Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. 
  • Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. 
  • Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. 
  • Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials. 
  • Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. 
  • Efficacy of oral sucralfate suspension in prevention and treatment of chemotherapy-induced mucositis. 
  • Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. 
  • Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks. 
  • Efficient trial designs to reduce placebo requirements. 
  • Electroconvulsive therapy: how effective is it? 
  • Electronic health records to facilitate clinical research. 
  • Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. 
  • Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. 
  • Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. 
  • Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. 
  • Embedding clinical interventions into observational studies. 
  • Emergence of depression during early abstinence in depressed and non-depressed women smokers. 
  • Emerging clinical applications of RNA. 
  • Emerging immunotherapies for autoimmune kidney disease. 
  • Emerging pharmacotherapy for cancer patients with cognitive dysfunction. 
  • Emerging therapeutic approaches in the management of retinal angiogenesis and edema. 
  • Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitors. 
  • Emerging treatment options for patients with castration-resistant prostate cancer. 
  • Emory Angioplasty Versus Surgery Trial (EAST): design, recruitment, and baseline description of patients. 
  • Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG. 
  • Enabling patient-reported outcome measures in clinical trials, exemplified by cardiovascular trials. 
  • End point selection in acute decompensated heart failure clinical trials: economic end points. 
  • End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. 
  • End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. 
  • End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. 
  • Endoglin Targeting: Lessons Learned and Questions That Remain. 
  • Endovascular intervention for acute ischemic stroke in light of recent trials. 
  • Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. 
  • Engineered transcription factors for therapeutic angiogenesis. 
  • Enhancing Repetitive Transcranial Magnetic Stimulation Effects for Depression Treatment: Navigare Necesse Est-and Smart Clinical Trial Designs. 
  • Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. 
  • Enhancing safety and outcomes with the newer antithrombotic and antiplatelet agents. 
  • Enhancing the technology of clinical trials and the trials model to evaluate newly developed, targeted antidepressants. 
  • Enhancing the value of clinical trials: the role of data sharing. 
  • Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. 
  • Enrollment and Racial Disparities in Cancer Treatment Clinical Trials in North Carolina. 
  • Enrollment and Retention of Men and Women in Health Services Research and Development Trials. 
  • Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. 
  • Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. 
  • Enrollment of Older Patients, Women, and Racial/Ethnic Minority Groups in Contemporary Acute Coronary Syndrome Clinical Trials: A Systematic Review. 
  • Enrollment of patients with lung and colorectal cancers onto clinical trials. 
  • Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. 
  • Enrollment of women in cardiovascular clinical trials. 
  • EpCAM: A new therapeutic target for an old cancer antigen. 
  • Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. 
  • Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. 
  • Epidermal growth factor receptor-targeted therapy for pancreatic cancer. 
  • Epigenetic mechanisms underlying diet-sourced compounds in the prevention and treatment of gastrointestinal cancer. 
  • Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. 
  • Equipoise in Clinical Trials: Enough Uncertainty in Whose Opinion? 
  • Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. 
  • Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. 
  • Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop. 
  • Estimating Clinical Trial Bleeding Events Using Electronic Health Record Data. 
  • Estimating the magnitude of clinical benefit of local therapy in patients with DCIS. 
  • Estimation of Body Fat Percentage for Clinical Pharmacokinetic Studies in Children. 
  • Estimation of therapeutic gain in clinical trials involving hyperthermia and radiotherapy. 
  • Ethical dilemmas in continuing a zidovudine trial after early termination of similar trials. 
  • Ethical issues in research in complementary and alternative medicine. 
  • Ethical ramifications of alternative means of recruiting research participants from cancer registries. 
  • Ethical responsibilities toward indirect and collateral participants in pragmatic clinical trials. 
  • Ethics in the quest for transplant tolerance. 
  • Ethics of placebo-controlled trials of zidovudine to prevent the perinatal transmission of HIV in the Third World. 
  • Eureka! It's a negative study! 
  • Evaluating the Coverage of the HL7 ® FHIR ® Standard to Support eSource Data Exchange Implementations for use in Multi-Site Clinical Research Studies. 
  • Evaluating the adequacy of disease control in patients with rheumatoid arthritis: a RAND appropriateness panel. 
  • Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. 
  • Evaluation of Representation of Women as Authors in Pivotal Trials Supporting US Food and Drug Administration Approval of Novel Cardiovascular Drugs. 
  • Evaluation of daunorubicin (NSC-82151) and methotrexate (NSC-740) in combination as a remission maintenance regimen in the treatment of acute leukemia. 
  • Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. 
  • Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ) SST Report Number 19. 
  • Evaluation of the left ventricle by two-dimensional echocardiography. 
  • Evaluative Outcomes in Direct Extraction and Use of EHR Data in Clinical Trials. 
  • Evidence for the treatment of borderline personality disorder. 
  • Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). 
  • Evidence supporting the use of bone morphogenetic proteins for spinal fusion surgery. 
  • Evidence-Based Practical Guidance for the Antithrombotic Management in Patients With Coronavirus Disease (COVID-19) in 2020. 
  • Evidence-based community consultation for traumatic brain injury. 
  • Evidence-based guidelines for pediatric clinical trials: focus on StaR Child Health. 
  • Evidence-based management of bullous pemphigoid. 
  • Evidence-based mental health use of anticonvulsants during pregnancy. 
  • Evidence-based oral transmucosal fentanyl citrate (OTFC) dosing guidelines. 
  • Evidence-based treatment of psychiatric disorders with comorbid medical illnesses: the need for large simple clinical trials. 
  • Evolution of the concept of focal therapy for prostate cancer. 
  • Evolving Landscape of Clinical Trials in Heart Failure: Patient Populations, Endpoint Selection, and Regions of Enrollment. 
  • Examination of the utility of psychotherapy for patients with treatment resistant depression: a systematic review. 
  • Examining biology and pharmacology-based hypotheses in the PLATO trial. 
  • Examining the challenges of recruiting women into a cardiac rehabilitation clinical trial. 
  • Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. 
  • Executive summary of AAPM Report Task Group 113: Guidance for the physics aspects of clinical trials. 
  • Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesity. 
  • Exercise therapy across the prostate cancer continuum. 
  • Exercise therapy as treatment for cardiovascular and oncologic disease after a diagnosis of early-stage cancer. 
  • Exogenous hormone use and meningioma risk: what do we tell our patients? 
  • Expanding Evidence for Clinical Care of Older Adults: Beyond Clinical Trial Traditions and Finding New Approaches. 
  • Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. 
  • Experience with a cross-study endpoint review committee for AIDS clinical trials. Terry Beirn Community Programs for Clinical Research on AIDS. 
  • Experience with irinotecan for the treatment of malignant glioma. 
  • Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity. 
  • Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). 
  • Exposure-Response Analysis of Micafungin in Neonatal Candidiasis: Pooled Analysis of Two Clinical Trials. 
  • Extended-release carbamazepine capsules as monotherapy in bipolar disorder : pooled results from two randomised, double-blind, placebo-controlled trials. 
  • Extended-release niacin for modifying the lipoprotein profile. 
  • Extending principles learned in model systems to clinical trials design. 
  • External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models. 
  • External beam radiation therapy for clinically localized prostate cancer: when and how we optimize with concurrent hormonal deprivation. 
  • Extracorporeal membrane oxygenation for neonatal and pediatric respiratory failure: an evidence-based review of the past decade (2002-2012). 
  • Extracorporeal shock wave lithotripsy. An update. 
  • Eye-tracking, attention and amphetamine challenge 
  • FPIN's clinical inquiries. Angiotensin blockade in patients with diabetic nephropathy. 
  • Factors affecting patient enrollment in radiology clinical trials: a case study of the American College of Radiology Imaging Network. 
  • Factors affecting the incidence of infectious morbidity after radical hysterectomy. 
  • Factors associated with African Americans' enrollment in a national cancer genetics registry. 
  • Factors associated with biomedical research participation within community-based samples across 3 National Cancer Institute-designated cancer centers. 
  • Factors associated with reporting results for pulmonary clinical trials in ClinicalTrials.gov. 
  • Factors influencing the participation of gastroenterologists and hepatologists in clinical research. 
  • Factors that influence practitioners' interpretations of evidence from alternative medicine trials: a factorial vignette experiment embedded in a national survey. 
  • Failure of mean red cell volume to serve as a biologic marker for alcoholism in narcotic dependence. A randomized control trial. 
  • Family patterns of decision-making in pediatric clinical trials 
  • Far beyond informed consent. US research institutions keep close watch on OPRR's suspensions. 
  • Feasibility of Cancer Clinical Trial Enrollment Goals Based on Cancer Incidence. 
  • Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: position statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-Sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. 
  • Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. 
  • Fibrinolysis for acute myocardial infarction: the future is here and now. 
  • Fibromatoses in childhood: the desmoid/fibromatosis complex. 
  • Financial Toxicity and Equitable Access to Clinical Trials. 
  • Finding Means to Fulfill the Societal and Academic Imperative for Open Data Access and Sharing. 
  • Findings on Surveillance Imaging After Preoperative Partial Breast Irradiation for Early Stage Breast Cancer. 
  • First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 4: pre-clinical efficacy and complication data required to justify a clinical trial. 
  • First- and second-generation antipsychotics. 
  • Fit for the future: empowering clinical trials with digital technology. 
  • Five analytic challenges in working with electronic health records data to support clinical trials with some solutions. 
  • Fixing the heart: must the brain pay the price? 
  • Flow cytometry analysis of adenosine deaminase (ADA) expression: a simple and reliable tool for the assessment of ADA-deficient patients before and after gene therapy. 
  • Fluconazole pharmacokinetics and safety in premature infants. 
  • Fluorouracil and leucovorin in advanced breast cancer. 
  • Fluoxetine versus trazodone in the treatment of outpatients with major depression. 
  • Focal therapy for prostate cancer: possibilities and limitations. 
  • Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. 
  • Forms of atypical depression and their response to antidepressant drugs. 
  • Frequency and Acceptability of Adverse Events After Anterior Cervical Discectomy and Fusion: A Survey Study From the Cervical Spine Research Society. 
  • Frequency estimator for assessing of follow-on biologics. 
  • Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. 
  • Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. 
  • From HIRMIT to the Cape May Lighthouse. Revascularization reconsidered in very high risk patients at the Duke Heart Center. 
  • From thrombolytic megatrials to clinical policy-making: facing the facts. 
  • From trial and error to trial simulation. Part 2: an appraisal of current beliefs in the design and analysis of clinical trials for antidepressant drugs. 
  • Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. 
  • Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. 
  • Fundamentals for oncology nurse/data managers--preparing for a new role. 
  • G-CSF as prophylaxis of febrile neutropenia in SCLC. 
  • GDNF in treatment of Parkinson's disease: response to editorial. 
  • GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. 
  • GP IIb/IIIa blockade in elective percutaneous coronary intervention. 
  • Gaining Efficiency in Clinical Trials With Cardiac Biomarkers: JACC Review Topic of the Week. 
  • Gallbladder density and iodine concentration in humans during oral cholecystography. A comparison of iopanoic acid and iopronic acid. 
  • Gastrointestinal microbleeding: comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents. 
  • Gefitinib for refractory advanced non-small-cell lung cancer. 
  • Gefitinib therapy for non-small cell lung cancer. 
  • Gemtuzumab ozogamicin: is there room for salvage? 
  • Gender differences in antidepressant and activating-drug effects on self-perceptions 
  • Gender, racial, and ethnic disclosure in NIH K-Award funded diabetes and obesity clinical trials. 
  • Gene therapies for hemophilia hit the mark in clinical trials. 
  • Gene therapy for glycogen storage diseases. 
  • Gene therapy for prostate cancer. 
  • Gene therapy for prostate cancer: where are we now? 
  • Gene therapy for the prevention of vein graft disease. 
  • General guidelines for clinical bacteriology. Infectious Diseases Society of America and the Food and Drug Administration. 
  • Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). 
  • Generation and Characterization of a Bivalent HIV-1 Subtype C gp120 Protein Boost for Proof-of-Concept HIV Vaccine Efficacy Trials in Southern Africa. 
  • Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. 
  • Genetic engineering of mesenchymal stem cells and its application in human disease therapy. 
  • Genetic targeting for cardiovascular therapeutics: are we near the summit or just beginning the climb? 
  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 
  • Genetics. FDA races in wrong direction. 
  • Geriatric assessment with management in cancer care: Current evidence and potential mechanisms for future research. 
  • Gerotechnology for Older Adults With Cardiovascular Diseases: JACC State-of-the-Art Review. 
  • Getting a handle on process and change in CBT for chronic pain. 
  • Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. 
  • Global cardiovascular device innovation: Japan-USA synergies: Harmonization by Doing (HBD) program, a consortium of regulatory agencies, medical device industry, and academic institutions. 
  • Global prevention of HIV infection for neglected populations: men who have sex with men. 
  • Globalization of heart failure clinical trials: a systematic review of 305 trials conducted over 16 years. 
  • Globalization of pediatric research: analysis of clinical trials completed for pediatric exclusivity. 
  • Glocal clinical registries: pacemaker registry design and implementation for global and local integration--methodology and case study. 
  • Glucose vs sucrose in oral rehydration solutions for infants and young children with rotavirus-associated diarrhea. 
  • Glutamine: role in critical illness and ongoing clinical trials. 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: pathophysiologic foundation and clinical findings. 
  • Good Clinical Practice Guidance and Pragmatic Clinical Trials: Balancing the Best of Both Worlds. 
  • Gordon's first law. 
  • Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect? 
  • Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. 
  • Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. 
  • Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes. 
  • Growth as a part of the composite endpoint in paediatric antiretroviral clinical trials. 
  • Growth factors for therapeutic angiogenesis in peripheral arterial disease. 
  • Guidance for researchers developing and conducting clinical trials in practice-based research networks (PBRNs). 
  • Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic. 
  • Guidelines for assessing immunocompetency in clinical trials for autoimmune diseases. 
  • Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the ad hoc Committee, American Heart Association. 
  • Guidelines for clinical trials of frontal fibrosing alopecia: consensus recommendations from the International FFA Cooperative Group (IFFACG). 
  • Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. 
  • Guidelines for quality assurance in multicenter trials: a position paper. 
  • Guidelines for trials of behavioral treatments for recurrent headache, first edition: American Headache Society Behavioral Clinical Trials Workgroup. 
  • Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. 
  • HIV Research for Prevention 2018: From Research to Impact Conference Summary and Highlights. 
  • HIV infection in vaccinated volunteers. 
  • HIV therapeutics: an emerging science. 
  • HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. 
  • HIV vaccine development at Duke University Medical Center. 
  • HIV-1 vaccines and adaptive trial designs. 
  • Haploidentical transplantation for leukemia. 
  • Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review. 
  • Harms, benefits, and the nature of interventions in pragmatic clinical trials. 
  • Healing prayer outcomes studies: consensus recommendations. 
  • Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. 
  • Health Insurance Payer Type and Ethnicity Are Associated with Cancer Clinical Trial Enrollment Among Adolescents and Young Adults. 
  • Health policy in stroke: translating what we know into what we do. 
  • Health-related quality of life and symptom management research sponsored by the National Cancer Institute. 
  • Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. 
  • Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues. 
  • Heart Failure Site-Based Research in the United States: Results of the Heart Failure Society of America Research Network Survey. 
  • Heart failure after myocardial infarction: A good heart is hard to find. 
  • Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). 
  • HeartMate® II continuous-flow left ventricular assist system. 
  • Heart Failure Collaboratory Statement on Clinical Trials in the Landscape of COVID-19. 
  • Hematopoietic cell transplantation for autoimmune disease: updates from Europe and the United States. 
  • Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. 
  • Hemorrhagic Stroke in Children and Adults With Sickle Cell Anemia: The Post-STOP Cohort. 
  • Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. 
  • Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 
  • Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. 
  • Hepatitis B immunization: a potential incentive to HIV vaccine trial participation in Thailand? 
  • Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. 
  • Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. 
  • Hierarchical modeling: its time has come. 
  • High incarceration rates among black men enrolled in clinical studies may compromise ability to identify disparities. 
  • High-dose cyclophosphamide (NSC-26271) therapy in childhood acute leukemia. 
  • High-dose cytarabine and total body irradiation with or without cyclophosphamide as a preparative regimen for marrow transplantation for acute leukemia. 
  • High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. 
  • High-frequency oscillatory ventilation compared with conventional mechanical ventilation in the treatment of respiratory failure in preterm infants. 
  • Higher urine desmosine levels are associated with mortality in patients with acute lung injury. 
  • Highlights from American Heart Association, November 4-7, 2007, Orlando, Florida, USA. Late-breaking trials summary. 
  • Highlights from the 56th annual scientific sessions of the American College of Cardiology: March 25 to 27, 2007, Atlanta, Georgia. 
  • Highlights from the 71st American Heart Association Scientific Sessions: November 8 to 11, 1998. 
  • Highlights from the American College of Cardiology 48th Annual Scientific Sessions: March 7 to 10, 1999. 
  • Highlights from the American Heart Association annual scientific sessions 2002: November 17 to 20, 2002. 
  • Highlights of the 2008 Scientific Sessions of the Heart Failure Society of America. Toronto, Ontario, Canada, September 20-23, 2008. 
  • Hospital participation in clinical trials for patients with acute myocardial infarction: Results from the National Cardiovascular Data Registry. 
  • Hospital-acquired complications in a randomized controlled clinical trial of a geriatric consultation team. 
  • Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. 
  • Host-Directed Therapies for Tuberculosis. 
  • How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease. 
  • How Biomedical HIV Prevention Trials Incorporate Behavioral and Social Sciences Research: A Typology of Approaches. 
  • How can we draw the line between clinical care and medical research. 
  • How common are ALS plateaus and reversals? 
  • How much do we gain by reducing time to reperfusion therapy? 
  • How much radiation is the chemotherapy worth in advanced head and neck cancer? 
  • How much vitamin D should I take? 
  • How much zidovudine is safe for children with advanced HIV? 
  • How to Conduct Clinical Trials in Children: A Tutorial. 
  • Hsp90, an unlikely ally in the war on cancer. 
  • Human immunodeficiency virus vaccine development in developing countries: are efficacy trials feasible? 
  • Human immunodeficiency virus vaccines. 
  • Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. 
  • Hyperhidrosis in social anxiety disorder. 
  • Hyperkalemia: treatment options. 
  • Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings. 
  • Hyperlipidemia in children and adolescents. 
  • Hyperthermia: an overview of current progress and problems. 
  • Hypofractionation for prostate cancer: a critical review. 
  • Hypotensive effects of clonidine and chlorthalidone. Controlled clinical trial of drugs administered singly and in combination. 
  • Hypoxia, angiogenesis, and lung cancer. 
  • ICH-E9 reflections and considerations. 
  • IPLEX and the telephone game: the difficulty in separating myth from reality on the internet. 
  • Ibrutinib: a new targeted therapy for hematologic cancers. 
  • Identification and assessment of prognostic factors. 
  • Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). 
  • Identification of population at risk for future Clostridium difficile infection following hospital discharge to be targeted for vaccine trials. 
  • Identified Enrollment Challenges of Adolescent and Young Adult Patients on the Nonchemotherapy Arm of Children's Oncology Group Study ARST1321. 
  • Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study. 
  • Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. 
  • Identifying a patient-centered outcome measure for a comparative effectiveness treatment trial in myasthenia gravis. 
  • Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals. 
  • Identifying quality of life outcome patterns to inform treatment choices in ischemic cardiomyopathy. 
  • If histology matters.. 
  • Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. 
  • Imaging surrogate end points in heart failure trials. 
  • Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. 
  • Immune monitoring. 
  • Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy. 
  • Immunotherapeutic targeting of Wilms' tumor protein. 
  • Immunotherapy approaches for malignant glioma from 2007 to 2009. 
  • Immunotherapy for gynaecological malignancies. 
  • Immunotherapy for osteosarcoma: Where do we go from here? 
  • Immunotherapy for primary brain tumors: no longer a matter of privilege. 
  • Immunotherapy of cancer using dendritic cells. 
  • Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting. 
  • Impact of Funding Source on Clinical Trial Results Including Cardiovascular Outcome Trials. 
  • Impact of a geriatric consultation team on discharge placement and repeat hospitalization. 
  • Impact of age and comorbidity on treatment and outcomes in elderly cancer patients. 
  • Impact of concurrent surgical valve procedures in patients receiving continuous-flow devices. 
  • Impact of early personal-history characteristics on the Pace of Aging: implications for clinical trials of therapies to slow aging and extend healthspan. 
  • Impact of intensive lipid modulation on angiographically defined coronary disease: clinical implications. 
  • Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. 
  • Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy. 
  • Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. 
  • Impact of vaccine type on HIV-1 vaccine elicited antibody durability and B cell gene signature. 
  • Impediments to clinical research in the United States. 
  • Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. 
  • Implantable cardioverter-defibrillators for primary prevention: how do the data pertain to the aged? 
  • Implementation considerations for multisite clinical trials with cognitive neuroscience tasks. 
  • Implementation of echocardiography core laboratory best practices: a case study of the PARTNER I trial. 
  • Implementation of remote 3-dimensional image guided radiation therapy quality assurance for radiation therapy oncology group clinical trials. 
  • Implications of Left Ventricular Geometry in Low-Flow Aortic Stenosis: A PARTNER 2 Trial Subanalysis. 
  • Implications of geographical variation on clinical outcomes of cardiovascular trials. 
  • Important sources of variability in clinical studies of neutralizing antibodies against interferon beta. 
  • Improved outcome in heart failure. 
  • Improved surgeon performance in clinical trials: an analysis of quality assurance audits from the American College of Surgeons Oncology Group. 
  • Improving Cardiovascular Drug and Device Development and Evidence Through Patient-Centered Research and Clinical Trials: A Call to Action From the Value in Healthcare Initiative's Partnering With Regulators Learning Collaborative. 
  • Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team. 
  • Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. 
  • Improving Quality and Consistency in NRG Oncology Radiation Therapy Oncology Group 0631 for Spine Radiosurgery via Knowledge-Based Planning. 
  • Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. 
  • Improving early clinical trial phase identification of promising therapeutics. 
  • Improving hypertension control: impact of computer feedback and physician education. 
  • Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy. 
  • Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma. 
  • Improving recovery following cardiac surgery: a randomized clinical trial. 
  • Improving the Evidence Base for Treating Older Adults With Cancer: American Society of Clinical Oncology Statement. 
  • Improving the assessment of heart toxicity for all new drugs through translational regulatory science. 
  • Improving the chance of recovery from the short- and long-term consequences of depression. 
  • Improving the clinical diagnosis of stroke. 
  • Improving the methodologic and ethical validity of best supportive care studies in oncology: lessons from a systematic review. 
  • Improving the quality of care for women with cardiovascular disease: report of a DCRI Think Tank, March 8 to 9, 2007. 
  • Imputation method adjusted for covariates for nonrespondents in instruments with applications. 
  • In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. 
  • In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet. 
  • Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. 
  • Incidence and predictors of appropriate therapies delivered by the implantable cardioverter defibrillator in patients with ischemic cardiomyopathy: a systematic review. 
  • Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials. 
  • Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. 
  • Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project. 
  • Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches. 
  • Increasing Black, Indigenous and People of Color participation in clinical trials through community engagement and recruitment goal establishment. 
  • Increasing Racial and Ethnic Diversity in Cancer Clinical Trials: An American Society of Clinical Oncology and Association of Community Cancer Centers Joint Research Statement. 
  • Increasing proportion of clinical trials using noninferiority end points. 
  • Increasing weight-bearing physical activity and calcium intake for bone mass growth in children and adolescents: a review of intervention trials. 
  • Incretin mimetics as emerging treatments for type 2 diabetes. 
  • Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 
  • Induction chemotherapy: to use or not to use? That is the question. 
  • Induction of immunity to human immunodeficiency virus type-1 by vaccination. 
  • Inference for clinical trials with some protocol amendments. 
  • Inference on treatment effects for targeted clinical trials under enrichment design. 
  • Inflammation and Immune Response in Arrhythmogenic Cardiomyopathy: State-of-the-Art Review. 
  • Influence of Clinical Trials of Acute Coronary Syndrome Beyond the Primary Hypothesis: A Systematic Review. 
  • Influence of WR 2721 on radiation response of canine soft tissue sarcomas. 
  • Influence of clinical trial enrollment on the quality of care and outcomes for patients with non-ST-segment elevation acute coronary syndromes. 
  • Influence of clinical trial participation on subsequent antithrombin use. 
  • Influence of imprecision on ROC curve analysis for cardiac markers. 
  • Infrastructure to Support Accrual of Older Adults to National Cancer Institute Clinical Trials. 
  • Inhibition of platelet monoamine oxidase in depressed subjects treated with phenelzine. 
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 
  • Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. 
  • Initial Content Validation and Roadmap for a New Patient-Reported Outcome Measure of Pain Intensity. 
  • Initial functional and economic status of patients with multivessel coronary artery disease randomized in the Bypass Angioplasty Revascularization Investigation (BARI). 
  • Initial therapy of hypertension. 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Innovations in HIV-1 Vaccine Design. 
  • Innovations in infertility: a comprehensive analysis of the ClinicalTrials.gov database. 
  • Innovations in urology from military medicine. 
  • Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children. 
  • Innovative Thinking on Endpoint Selection in Clinical Trials. 
  • Innovative clinical trial design for pediatric therapeutics. 
  • Innovative design and analysis for rare disease drug development. 
  • Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 
  • Insights derived from the thrombolysis and angioplasty in myocardial infarction (TAMI) trials. 
  • Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. 
  • Integrating ancillary studies in a large clinical trial: the design and rationale of the APEX library. 
  • Integrative care: what the research shows. 
  • Intensity-modulated radiation therapy for anal cancer: toxicity versus outcomes. 
  • Intensity-modulated radiation therapy in gynecologic malignancies. 
  • Interactive associations of depression and sleep apnea with adverse clinical outcomes after acute myocardial infarction. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. 
  • Intermediate outcomes: diagnostic and therapeutic impact. 
  • International advances in the treatment of social phobia. 
  • International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies. 
  • International guidance on the selection of patient-reported outcome measures in clinical trials: a review. 
  • International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. 
  • International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials. 
  • International variation in the use of evidence-based medicines for acute coronary syndromes. 
  • International variations in the clinical, diagnostic, and treatment characteristics of emergency department patients with acute heart failure syndromes. 
  • Interpretation of clinical trial results: a committee opinion. 
  • Interpreting measures of treatment effect in cancer clinical trials. 
  • Interpreting the TRITON results in light of the event adjudication process. 
  • Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. 
  • Interstitial hyperthermia in combination with brachytherapy. 
  • Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. 
  • Intra-Target Microdosing (ITM): A Novel Drug Development Approach Aimed at Enabling Safer and Earlier Translation of Biological Insights Into Human Testing. 
  • Intra-aortic balloon pump trials: questions, answers, and unresolved issues. 
  • Intraoperatic electron beam irradiation in pancreatic cancer. 
  • Intraoperative irradiation: current and future status. 
  • Intravenous metronidazole or clindamycin with tobramycin for therapy of pelvic infections. 
  • Intravenous thrombolysis in acute myocardial infarction. 
  • Introduction to a Special Issue of the Journal of Immunological Methods: Building global resource programs to support HIV/AIDS clinical trial studies. 
  • Introduction to the CATIE special section. 
  • Introduction to the special section on CATIE baseline data: practical clinical trials in psychiatry: studies of schizophrenia from the CATIE network. 
  • Introduction: fusidic acid enters the United States. 
  • Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia. 
  • Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. 
  • Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. 
  • Investigational therapies for non-muscle invasive bladder cancer. 
  • Investigative guidelines for alopecia areata. 
  • Iron deficiency and hair loss: the jury is still out. 
  • Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic? 
  • Is age-related macular degeneration a manifestation of systemic disease? New prospects for early intervention and treatment. 
  • Is developing an HIV-1 vaccine possible? 
  • Is there sex bias in the management of coronary artery disease? 
  • Is this a clinical trial? And should it be registered? 
  • Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. 
  • Ischemic stroke survivors' opinion regarding research utilizing exception from informed consent. 
  • Issues affecting minority participation in research studies of Alzheimer disease. 
  • Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. 
  • Issues in regulatory guidelines for data monitoring committees. 
  • JCL roundtable: Omega-3 fatty acids and cardiovascular outcomes. 
  • Joining a Multicenter Clinical Trial. 
  • Journal of Biopharmaceutical Statistics. From the editors. 
  • Kidney cancer. Clinical practice guidelines in oncology. 
  • Knowledge Gaps in Cardiovascular Care of the Older Adult Population: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Geriatrics Society. 
  • Knowledge and Insights Vested in Us by the VEST. 
  • LINAC based stereotactic radiosurgery for multiple brain metastases: guidance for clinical implementation. 
  • Laparoscopic resection for colon cancer: a favorable view. 
  • Late adverse events after drug-eluting stent implantation. 
  • Late treatment of HIV infection--is it better? 
  • Latent-model robustness in joint models for a primary endpoint and a longitudinal process. 
  • Launching Effectiveness Research to Guide Practice in Neurosurgery: A National Institute Neurological Disorders and Stroke Workshop Report. 
  • Learning from recent trials and shaping the future of acute heart failure trials. 
  • Left Ventricular Hypertrophy and Clinical Outcomes Over 5 Years After TAVR: An Analysis of the PARTNER Trials and Registries. 
  • Lessons from SADHART, ENRICHD, and other trials. 
  • Lessons learned from HIV-1 vaccine trials: new priorities and directions. 
  • Lessons learned from human HIV vaccine trials. 
  • Lessons learned from negative clinical trials evaluating antithrombotic therapy for ischemic heart disease. 
  • Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy. 
  • Letrozole in the treatment of breast cancer. 
  • Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs. 
  • Leveraging Patient Preference Information in Medical Device Clinical Trial Design. 
  • Leveraging a Sturge-Weber Gene Discovery: An Agenda for Future Research. 
  • Leveraging electronic health records for clinical research. 
  • Liability issues for data monitoring committee members. 
  • Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia. 
  • Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. 
  • Limitations in efficacy of antidepressant monotherapy. 
  • Lipid changes associated with antiretroviral therapy: results differ by reporting approach. 
  • Lipid formulations of amphotericin B for empirical treatment of fever and neutropenia. 
  • Lipids and diabetic retinopathy. 
  • Liposomal amphotericin B: clinical experience and perspectives. 
  • Literacy and informed consent: a case for literacy screening in glaucoma research. 
  • Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy. 
  • Lithium may slow progression of amyotrophic lateral sclerosis, but further study is needed. 
  • Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. 
  • Local anaesthetic wound infiltration for postcaesarean section analgesia: A systematic review and meta-analysis. 
  • Lonafarnib for cancer and progeria. 
  • Long term use of intravenous immune globulin in patients with primary immunodeficiency diseases: inadequacy of current dosage practices and approaches to the problem. 
  • Long-term Consequences of Pelvic Irradiation: Toxicities, Challenges, and Therapeutic Opportunities with Pharmacologic Mitigators. 
  • Long-term ambulatory therapy with prazosin versus placebo for chronic heart failure: relation between clinical response and left ventricular function at rest and during exercise. 
  • Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. 
  • Long-term follow-up of men with male pattern baldness treated with topical minoxidil. 
  • Long-term outcome of endovascular stenting for symptomatic basilar artery stenosis. 
  • Long-term treatment of calcium nephrolithiasis with potassium citrate. 
  • Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. 
  • Low-grade glioma. 
  • Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors with percutaneous coronary intervention in acute coronary syndromes. 
  • Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial. 
  • Lymphoblastic lymphoma in children--a randomized trial comparing LSA2-L2 with the A-COP+ therapeutic regimen: a Pediatric Oncology Group Study. 
  • MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury. 
  • MEK inhibition in the treatment of advanced melanoma. 
  • Machine learning to define phenotypes and outcomes of patients hospitalized for heart failure with preserved ejection fraction: Findings from ASCEND-HF. 
  • Major bleeding: management and risk reduction in acute coronary syndromes. 
  • Making Sense of Hypertension Guidelines. 
  • Malaria vaccine efficacy: the difficulty of detecting and diagnosing malaria. 
  • Malaria vaccine trials in pregnant women: An imperative without precedent. 
  • Management of antiretroviral therapy. 
  • Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. 
  • Management of posttraumatic stress disorder: diagnostic and therapeutic issues. 
  • Managing accrual in cooperative group clinical trials. 
  • Maternal immunization: opportunities for scientific advancement. 
  • Maximizing retention in community-based clinical trials 
  • Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. 
  • Maximizing the benefits of thrombolytic therapy for acute myocardial infarction. 
  • Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. 
  • Measuring activities in clinical trials using random work sampling: implications for cost-effectiveness analysis and measurement of the intervention. 
  • Measuring results of treatment of PTSD. 
  • Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials. 
  • Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. 
  • Mechanism of protective effects of ACE inhibition on coronary artery disease. 
  • Medical Expulsive Therapy for Urinary Stones: Future Trends and Knowledge Gaps. 
  • Medical advances in the treatment of congestive heart failure. 
  • Medication misadventures in older adults: literature from 2013. 
  • Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. 
  • Medicine. A portfolio model of drug development for tuberculosis. 
  • Medicine. The need for a global HIV vaccine enterprise. 
  • Medrogestone: a prospective study in the pharmaceutical management of benign prostatic hyperplasia. 
  • Meeting report ESC forum on drug eluting stents, European Heart House, Nice, 27-28 September 2007. 
  • Melanoma trials that defined surgical management: Overview of trials that established NCCN margin guidelines. 
  • Memory, language, and praxis in Alzheimer's disease: norms for outpatient clinical trial populations. 
  • Meningococcal tetravalent conjugate vaccine. 
  • Meperidine: a critical review. 
  • Mesenchymal Stem Cell Therapy in Stroke: A Systematic Review of Literature in Pre-Clinical and Clinical Research. 
  • Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. 
  • Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. 
  • Meta-analytic tools for medical decision making: a practical guide. 
  • Metabolic syndrome: evaluation of pathological and therapeutic outcomes. 
  • Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. 
  • Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research. 
  • Methodological considerations in the design and implementation of clinical trials. 
  • Methodological issues in developing new acute treatments for patients with bipolar illness. 
  • Methodological issues in negative symptom trials. 
  • Methods for comparing durability of immune responses between vaccine regimens in early-phase trials. 
  • Methods of testing feasibility for sequenced treatment alternatives to relieve depression (STAR*D). 
  • Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. 
  • Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. 
  • Micafungin: the US perspective. 
  • Mitogen-activated protein kinases in heart development and diseases. 
  • Mobilization of peripheral blood progenitor cells by hematopoietic growth factors. 
  • Modifiable barriers to enrollment in American ALS research studies. 
  • Modulating protein kinase C (PKC) to increase the efficacy of chemotherapy: stepping into darkness. 
  • Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution. 
  • Molecular surveillance of HIV-1 field strains in Nigeria in preparation for vaccine trials. 
  • Monitoring and ensuring safety during clinical research. 
  • Monitoring cellular immune responses to cancer immunotherapy. 
  • Monitoring liver safety in drug development: the GSK experience. 
  • Monitoring the quality of conduct of clinical trials: a survey of current practices. 
  • Monitoring versus interim analysis of clinical trials: a perspective from the pharmaceutical industry. 
  • Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. 
  • More on compulsory registration of clinical trials: GSK has created useful register. 
  • More salt, please. The DASH Steering Committee. 
  • Motor cortex stimulation and neuropathic facial pain. 
  • Multi-system verification of registrations for image-guided radiotherapy in clinical trials. 
  • Multicenter collaborative evaluation of a standardized serum bactericidal test as a prognostic indicator in infective endocarditis. 
  • Multicenter, double-blind, placebo-controlled trial of terfenadine suspension in the treatment of fall-allergic rhinitis in children. 
  • Multidimensional latent trait linear mixed model: an application in clinical studies with multivariate longitudinal outcomes. 
  • Multidisciplinary approach to the challenge of hemostasis. 
  • Multidisciplinary care of patients with early-stage breast cancer. 
  • Multifamily group treatment for veterans with traumatic brain injury: what is the value to participants? 
  • Multiple roles for HIV broadly neutralizing antibodies. 
  • Multiple-fraction-per-day external beam radiotherapy for adults with supratentorial malignant gliomas. 
  • Multipotent stem cells in cardiac regenerative therapy. 
  • Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. 
  • Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. 
  • Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. 
  • Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. 
  • Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. 
  • Mycophenolate mofetil in myasthenia gravis: the unanswered question. 
  • Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Myeloid growth factors. 
  • Myelotoxicity from chemotherapy. 
  • Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. 
  • Myonecrosis after revascularization procedures. 
  • NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. 
  • NCCN Guidelines Insights: Bone Cancer, Version 2.2017. 
  • NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. 
  • NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018. 
  • NCCN Task Force Report: mTOR inhibition in solid tumors. 
  • NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. 
  • NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms. 
  • NIH Consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 Pathology Working Group Report. 
  • NIH conference. HIV vaccine development: a progress report. 
  • National Depressive and Manic-Depressive Association consensus statement on the use of placebo in clinical trials of mood disorders. 
  • National Heart, Lung, And Blood Institute Clinical Proteomics Working Group report. 
  • National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. 
  • National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. 
  • National Institutes of Health StrokeNet During the Time of COVID-19 and Beyond. 
  • Native Tissue Prolapse Repairs: Comparative Effectiveness Trials. 
  • Natriuretic Peptide-guided therapy for heart failure. 
  • Natriuretic peptide-guided heart failure management. 
  • Natriuretic peptide-guided management in heart failure. 
  • Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. 
  • Natural history of renal cell carcinoma. 
  • Natural products and chronic hepatitis C virus. 
  • Navigating Nonessential Research Trials During COVID-19: The Push We Needed for Using Digital Technology to Increase Access for Rural Participants? 
  • Need for insulin therapy in type II diabetes mellitus. A randomized trial. 
  • Negative trials in nephrology: what can we learn? 
  • Neoadjuvant androgen-deprivation therapy prior to radical prostatectomy: con. 
  • Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. 
  • Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. 
  • Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. 
  • Neural modulation for hypertension and heart failure. 
  • Neurocognitive assessment in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial: development, methodology, and rationale. 
  • Neurofeedback treatment of epilepsy: from basic rationale to practical application. 
  • Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. 
  • Neuroinflammation in Alzheimer's disease. 
  • Neurologic impairment 10 years after optic neuritis. 
  • Never too old? Age should not be a barrier to enrollment in cancer clinical trials. 
  • New Perspectives in Rheumatology: Biomarkers as Entry Criteria for Clinical Trials of New Therapies for Systemic Lupus Erythematosus: The Example of Antinuclear Antibodies and Anti-DNA. 
  • New antifungal agents under development in children and neonates. 
  • New applications of gemcitabine and future directions in the management of pancreatic cancer. 
  • New drug application strategies for supraventricular arrhythmias. 
  • New drugs for children and adolescents with cancer: the need for novel development pathways. 
  • New drugs in prostate cancer. 
  • New insights into the role of antinuclear antibodies in systemic lupus erythematosus. 
  • New modalities of neurostimulation: high frequency and dorsal root ganglion. 
  • New policy on disclosure of interest for American College of Rheumatology Journals. 
  • New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. 
  • New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not let the perfect be the enemy of the good. 
  • New strategies in the management of acute coronary syndromes. 
  • New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor. 
  • New treatments for methicillin-resistant Staphylococcus aureus. 
  • Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. 
  • Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. 
  • Nicotine abstinence genotyping: assessing the impact on smoking cessation clinical trials. 
  • Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design. 
  • No effect of low-dose statins treatment on cerebral blood flow in humans with atherosclerotic cerebrovascular disease. 
  • No sex for science? Formative research on the acceptability and feasibility of a true contraceptive efficacy clinical trial. 
  • Non-Hodgkin's Lymphomas, version 3.2012. 
  • Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Non-cholinergic strategies for treating and preventing Alzheimer's disease. 
  • Nonemergency use of slow infusions of diazoxide. 
  • Nonocclusion and spontaneous recanalization rates in acute ischemic stroke: a review of cerebral angiography studies. 
  • Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience. 
  • Nonparametric tests for evaluation of biosimilarity in variability of follow-on biologics. 
  • Nonpharmacologic therapy in heart failure: an overview. 
  • Novel approaches to clinical trials: device-related infections. 
  • Novel oral anticoagulants: pharmacology, coagulation measures, and considerations for reversal. 
  • Novel therapeutic approaches to advanced prostate cancer. 
  • Novel therapies are changing treatment paradigms in metastatic prostate cancer. 
  • Nucleic acid aptamers and their complimentary antidotes. Entering an era of antithrombotic pharmacobiologic therapy. 
  • O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. 
  • OARSI Clinical Trials Recommendations: Design and conduct of clinical trials for hand osteoarthritis. 
  • OARSI Clinical Trials Recommendations: Design and conduct of clinical trials of lifestyle diet and exercise interventions for osteoarthritis. 
  • OARSI Clinical Trials Recommendations: Design and conduct of implementation trials of interventions for osteoarthritis. 
  • OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. 
  • Objective performance goals of safety and blood pressure efficacy for clinical trials of renal artery bare metal stents in hypertensive patients with atherosclerotic renal artery stenosis. 
  • Occult primary. 
  • Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications. 
  • Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. 
  • Off-label applications for SSRIs. 
  • Off-label uses for selective serotonin reuptake inhibitors. 
  • Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development. 
  • Ofloxacin: its pharmacology, pharmacokinetics, and potential for clinical application. 
  • Old drugs, new purpose: retooling existing drugs for optimized treatment of resistant tuberculosis. 
  • Older Adults in Clinical Research and Drug Development: Closing the Geriatric Gap. 
  • Older Patients With Acute Decompensated Heart Failure Who Live Alone: An Analysis From the REHAB-HF Trial. 
  • Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. 
  • On Two-stage Seamless Adaptive Design in Clinical Trials. 
  • On confirmation bias in imaging research. 
  • On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance. 
  • On sample size calculation based on odds ratio in clinical trials. 
  • On sample size calculation in bioequivalence trials. 
  • On sample size estimation and re-estimation adjusting for variability in confirmatory trials. 
  • On the assessment of dose proportionality: a comparison of two slope approaches. 
  • On the complexity of investigating chronic illness. 
  • On the estimation of total variability in assay validation. 
  • On the independence of data monitoring committee in adaptive design clinical trials. 
  • Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. 
  • One-year change in anterior cingulate cortex white matter microstructure: relationship with late-life depression outcomes. 
  • Online exclusive: functional integration of nursing research into a pediatric oncology cooperative group: finding common ground. 
  • Onset and duration of neuromuscular blockade following high-dose vecuronium administration. 
  • Ontario Cancer Research Ethics Board: lessons learned from developing a multicenter regional institutional review board. 
  • Open science: The open clinical trials data journey. 
  • Operationalizing Precision Cardiovascular Medicine: Three Innovations. 
  • Operative trials: the opportunity beckons-an update on the American College of Surgeons Oncology Group. 
  • Opioids. 
  • Opportunities for improving the therapeutic ratio for patients with sarcoma. 
  • Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week. 
  • Optimization of perfusion imaging for acute cerebral ischemia: review of recent clinical trials and recommendations for future studies. 
  • Optimized image acquisition for breast tomosynthesis in projection and reconstruction space. 
  • Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation Oncologists. 
  • Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. 
  • Optimizing operational efficiencies in early phase trials: The Pediatric Trials Network experience. 
  • Optimizing platelet P2Y12 inhibition for patients undergoing PCI. 
  • Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer. 
  • Optimizing the use of thrombolytics in ST-segment elevation myocardial infarction. 
  • Oral hydration rotavirus diarrhoea: a double blind comparison of sucrose with glucose electrolyte solution. 
  • Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. 
  • Oral typhoid vaccine Ty21a. 
  • Organ and function preservation: the role of surgery as the optimal primary modality or as salvage after chemoradiation failure. 
  • Organizational and physician factors associated with patient enrollment in cancer clinical trials. 
  • Oritavancin for acute bacterial skin and skin structure infections. 
  • Our vision for the American Heart Journal. 
  • Outcome methods used in clinical studies of Chiari malformation Type I: a systematic review. 
  • Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. 
  • Outcomes of diabetic patients following acute myocardial infarction: a review of the major thrombolytic trials. 
  • Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial. 
  • Outcomes-Based CV Imaging Research Endpoints and Trial Design: From Pixels to Patient Satisfaction. 
  • Outcomes-based evaluations supporting computer-assisted surgery and minimally invasive surgery for total hip arthroplasty. 
  • Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management. 
  • Overcoming obstacles in the design of cancer anorexia/weight loss trials. 
  • Overcoming recruitment challenges in palliative care clinical trials. 
  • Oversight mechanisms for clinical research. 
  • Oversight of financial conflicts of interest in commercially sponsored research in academic and nonacademic settings. 
  • Overview of bladder cancer trials in the Cancer and Leukemia Group B. 
  • Overview of registered studies in orthodontics: Evaluation of the ClinicalTrials.gov registry. 
  • Oxybutynin chloride in control of post-trasurethral vesical pain and spasm. 
  • Oxygen-Free Days as an Outcome Measure in Clinical Trials of Therapies for COVID-19 and Other Causes of New-Onset Hypoxemia. 
  • PAR-1 inhibitors: a novel class of antiplatelet agents for the treatment of patients with atherothrombosis. 
  • PARAGON-HF Clinical Trial Eligibility in a Population of Patients Hospitalized With Heart Failure. 
  • PET screening of carotid occlusion. 
  • PREVENTion of non-surgical bleeding by management of HeartMate II patients without anti-platelet therapy (PREVENT II) trial. 
  • Paediatric cardiovascular clinical trials: an analysis of ClinicalTrials.gov and the Food and Drug Administration Pediatric Drug Labeling Database. 
  • Palliative treatment of metastatic colorectal cancer: what is the optimal approach? 
  • Panobinostat for the management of multiple myeloma. 
  • Paroxetine: safety and tolerability issues. 
  • Participants' perspectives on safety monitoring in clinical trials. 
  • Participation in a Heart Failure Clinical Trial: Perspectives and Opportunities From the VICTORIA Trial and VICTORIA Simultaneous Registry. 
  • Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. 
  • Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. 
  • Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011. 
  • Patient Engagement Practices in Clinical Research among Patient Groups, Industry, and Academia in the United States: A Survey. 
  • Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study. 
  • Patient education level as a predictor of survival in lung cancer clinical trials. 
  • Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science. 
  • Patient reactions to confidentiality, liability, and financial aspects of informed consent in cardiology research. 
  • Patient safety in trials of therapy for acute ischemic stroke. 
  • Patient selection for percutaneous mitral valve repair: insight from early clinical trial applications. 
  • Patient selection in heart failure with preserved ejection fraction clinical trials. 
  • Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. 
  • Patient-Level Analysis of Watchman Left Atrial Appendage Occlusion in Practice Versus Clinical Trials. 
  • Patient-Reported Outcomes in Atrial Fibrillation Research: Results of a Clinicaltrials.gov Analysis. 
  • Patient-reported outcomes as end points and outcome indicators in solid tumours. 
  • Patient-reported outcomes assessment in cancer trials: evaluating and enhancing the payoff to decision making. 
  • Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. 
  • Patient-reported outcomes in the Translational Breast Cancer Research Consortium. 
  • Patients' understanding of oncology clinical endpoints: A literature review. 
  • Patients, physicians, and clinical trials: the other side of the coins. 
  • Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. 
  • Pediatric Antibacterial and Antifungal Trials From 2007 to 2017. 
  • Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. 
  • Pediatric cardiovascular drug trials, lessons learned. 
  • Pediatric cardiovascular safety: challenges in drug and device development and clinical application. 
  • Peer-reviewed publication of clinical trials completed for pediatric exclusivity. 
  • Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia. 
  • Pegfilgrastim: the promise of pegylation fulfilled. 
  • Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. 
  • Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale. 
  • Perception of Obesity in the Latino Population: Implications for Weight Loss Clinical Trials. 
  • Perceptions of the role of maternal nutrition in HIV-positive breast-feeding women in Malawi. 
  • Perifosine: update on a novel Akt inhibitor. 
  • Perioperative COX-2 inhibitors: knowledge and challenges. 
  • Peripheral arterial disease: an overview of endovascular therapies and contemporary treatment strategies. 
  • Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. 
  • Perspectives from man's best friend: National Academy of Medicine's Workshop on Comparative Oncology. 
  • Perspectives from the Society for Pediatric Research. Neonatal encephalopathy clinical trials: developing the future. 
  • Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participants. 
  • Perspectives on large-scale cardiovascular clinical trials for the new millennium. The Virtual Coordinating Center for Global Collaborative Cardiovascular Research (VIGOUR) Group. 
  • Pexelizumab: a novel therapy for myocardial ischemia-reperfusion. 
  • Pharmacogenetics in heart failure trials. 
  • Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. 
  • Pharmacoinvasive management of acute coronary syndrome in the setting of percutaneous coronary intervention: evidence-based, site- and spectrum-of-care strategies for optimizing patient outcomes in NSTE-ACS. 
  • Pharmacokinetic interactions between buprenorphine and antiretroviral medications. 
  • Pharmacokinetic studies in infants using minimal-risk study designs. 
  • Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults. 
  • Pharmacokinetics of levetiracetam. 
  • Pharmacologic studies in vulnerable populations: Using the pediatric experience. 
  • Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. 
  • Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use. 
  • Pharmacological treatment of elderly patients with acute coronary syndromes without persistent ST segment elevation. 
  • Pharmacotherapy for human immunodeficiency virus-associated nephropathy. 
  • Pharmacotherapy for post-traumatic stress disorder. 
  • Pharmacotherapy in stroke rehabilitation. 
  • Pharmacotherapy of disseminated histoplasmosis in patients with AIDS. 
  • Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. 
  • Pharmacotherapy of social anxiety disorder. 
  • Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines. 
  • Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma. 
  • Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. 
  • Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial. 
  • Phase II evaluation of aclarubicin in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. 
  • Phase II evaluation of etoposide in refractory multiple myeloma: a Southeastern Cancer Study Group Trial. 
  • Phase II study of etoposide for carcinoma of the prostate. 
  • Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. 
  • Phosphate homeostasis in CKD: report of a scientific symposium sponsored by the National Kidney Foundation. 
  • Physicians' preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs. 
  • Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants. 
  • Pipeline pharmacogenetics: a novel approach to integrating pharmaco-genetics into drug development. 
  • Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies. 
  • Planning the size and duration of a clinical trial studying the time to some critical event. 
  • Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? 
  • Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction. 
  • Platelet-Mediated Thrombosis: From Bench to Bedside. 
  • Platelet-derived growth factor receptors: a therapeutic target in solid tumors. 
  • Pneumonia after cardiac surgery: Experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network. 
  • Point/counterpoint: we do not need randomized clinical trials to demonstrate the superiority of proton therapy. 
  • Polyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccines. 
  • Pompe disease gene therapy. 
  • Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. 
  • Population Analysis of Anidulafungin in Infants to Older Adults With Confirmed or Suspected Invasive Candidiasis. 
  • Population and target considerations for triple-negative breast cancer clinical trials. 
  • Portfolio of clinical research in adult cardiovascular disease as reflected in ClinicalTrials.gov. 
  • Posaconazole. 
  • Post-procedure heparin: boon or burden? 
  • Post-traumatic stress disorder. 
  • Postcoronary thrombolysis management. 
  • Posterior approaches for symptomatic metastatic spinal cord compression. 
  • Postherpetic neuralgia in immunocompetent elderly people. 
  • Postoperative radiation therapy for lung cancer: where do we stand? 
  • Poststroke treatment: lost in translation. 
  • Posttraumatic stress disorder: diagnosis and epidemiology, comorbidity and social consequences, biology and treatment. 
  • Potential Association of the ISCHEMIA Trial With the Appropriate Use Criteria Ratings for Percutaneous Coronary Intervention in Stable Ischemic Heart Disease. 
  • Potential role of increased iron stores in diabetes. 
  • Power calculations for large multi-arm placebo-controlled studies of dichotomous outcomes. 
  • Practical Issues in Clinical Inspection Process. 
  • Preclinical and Coclinical Studies in Prostate Cancer. 
  • Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. 
  • Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
  • Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. 
  • Preeclampsia: multiple approaches for a multifactorial disease. 
  • Prehospital management of acute ST-elevation myocardial infarction: a time for reappraisal in North America. 
  • Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 
  • Preliminary report on the use of high-fidelity simulation in the training of study coordinators conducting a clinical research protocol. 
  • Preliminary results of a phase III trial of spontaneous animal tumors to heat and/or radiation: early normal tissue response and tumor volume influence on initial response. 
  • Preliminary study of carbamazepine in post-traumatic stress disorder. 
  • Preoperative Determinants of Quality of Life and Functional Capacity Response to Left Ventricular Assist Device Therapy. 
  • Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. 
  • Preoperative hyperthermia and radiation for soft tissue sarcomas: advantage of two vs one hyperthermia treatments per week. 
  • Preparation and Analysis of Peanut Flour Used in Oral Immunotherapy Clinical Trials. 
  • Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. 
  • Preparatory studies for possible HIV vaccine trials in northern Thailand. 
  • Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. 
  • Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic Predictive Instrument (TPI) Project results. 
  • Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. 
  • Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry. 
  • Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. 
  • Preventing childhood obesity in early care and education settings: lessons from two intervention studies. 
  • Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results. 
  • Prevention and health services delivery. 
  • Preview of a new trial of extracranial-to-intracranial arterial anastomosis: the carotid occlusion surgery study. 
  • Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop. 
  • Primary and key secondary results from the ROCKET AF trial, and their implications on clinical practice. 
  • Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. 
  • Primary systemic therapy in HER2-amplified breast cancer: a clinical review. 
  • Principles of drug treatment in children. 
  • Prioritization and Timing of Outcomes and Endpoints After Aneurysmal Subarachnoid Hemorrhage in Clinical Trials and Observational Studies: Proposal of a Multidisciplinary Research Group. 
  • Problems and advantages of an observational data base approach to evaluating the effect of therapy on outcome. 
  • Problems with the randomized discontinuation design. 
  • Proceedings from Duke resistant hypertension think tank. 
  • Proceedings from the Society of Interventional Radiology research consensus panel on critical limb ischemia. 
  • Process control analysis of IMRT QA: implications for clinical trials. 
  • Prognostic factors in the initial response to therapy by patients with advanced breast cancer. 
  • Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. 
  • Prognostic stratification in UPC: a role for assessing the value of conventional-dose and high-dose chemotherapy for unknown primary carcinoma. 
  • Prognostic value of the admission electrocardiogram in acute coronary syndromes. 
  • Progress culminating from ten years of clinical trials on thrombolysis for acute myocardial infarction. GUSTO-I Steering Committee. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Progress in HIV-1 vaccine development. 
  • Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses. 
  • Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. 
  • Prohemostatic agents to prevent perioperative blood loss. 
  • Promoting patient safety. 
  • Proper use and recognized role of TPN in the cancer patient. 
  • Prophylactic use of human leukocyte interferon after allogeneic marrow transplantation. 
  • Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. 
  • Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. 
  • Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. 
  • Proposed primary endpoints for use in clinical trials that compare treatment options for bloodstream infection in adults: a consensus definition. 
  • Prospect of rindopepimut in the treatment of glioblastoma. 
  • Prospective randomized double-blind comparison of moxalactam and tobramycin in treatment of urinary tract infections. 
  • Prospects for a safe COVID-19 vaccine. 
  • Prospects of immune checkpoint modulators in the treatment of glioblastoma. 
  • Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. 
  • Prostate-specific antigen endpoints in hormone-refractory prostate cancer. 
  • Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials. 
  • Protecting subjects, preserving trust, promoting progress II: principles and recommendations for oversight of an institution's financial interests in human subjects research. 
  • Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. 
  • Pruning the regulatory tree. 
  • PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. 
  • PsychDT Working Group: Report Psychosocial Aspects of Artificial Pancreas Systems. 
  • Psychosocial factors and coronary disease. A national multicenter clinical trial (ENRICHD) with a North Carolina focus. 
  • Psychosocial factors: role in cardiac risk and treatment strategies. 
  • Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment? 
  • Public disclosure of clinical research. 
  • Public reporting of black participation in anti-hypertensive drug clinical trials. 
  • Public sensationalism and clinical trials: how to address the challenges of science? 
  • Publication Rates of Heart Failure Clinical Trials Remain Low. 
  • Pulmonary hypertension and nitric oxide depletion in sickle cell disease. 
  • Pursuing progress in acute coronary syndromes. 
  • Putting Provenge in perspective. 
  • Putting Provenge in perspective. 
  • Quality Outcomes Database Spine Care Project 2012-2020: milestones achieved in a collaborative North American outcomes registry to advance value-based spine care and evolution to the American Spine Registry. 
  • Quality improvement methods as applied to a multicenter effectiveness trial--STAR*D. 
  • Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. 
  • Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress. 
  • Quantification metrics for telangiectasia using optical coherence tomography. 
  • Quantifying data quality for clinical trials using electronic data capture. 
  • Quantitative imaging biomarkers: a review of statistical methods for technical performance assessment. 
  • Quantitative imaging in oncology patients: Part 1, radiology practice patterns at major U.S. cancer centers. 
  • Quetiapine XR: current status for the treatment of major depressive disorder. 
  • REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis. 
  • RNA-Based Vaccines in Cancer Immunotherapy. 
  • RNA-transfected dendritic cells. 
  • RSNA Clinical Trials Methodology Workshop. 
  • RTOG quality assurance guidelines for clinical trials using hyperthermia administered by ultrasound. 
  • RTOG quality assurance guidelines for clinical trials using hyperthermia for deep-seated malignancy. 
  • RTOG quality assurance guidelines for clinical trials using hyperthermia. 
  • Racial and Ethnic Diversity in Studies Funded Under the Best Pharmaceuticals for Children Act. 
  • Racial diversity in uterine leiomyoma clinical studies. 
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Cancer Prevention and Control Committee. 
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Gastrointestinal Cancer Committee. 
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Genitourinary Cancer Committee. 
  • Radiation therapy for oligometastatic non-small cell lung cancer. 
  • Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey. 
  • Radiation therapy for resectable colon cancer. Is there a role in the modern chemotherapy era? 
  • Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant? 
  • Radiation therapy in the management of rectal cancer. 
  • Radiation-induced lung injury. Assessment, management, and prevention. 
  • Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. 
  • Randomised trial of plasma exchange in mild systemic lupus erythematosus. 
  • Randomization procedures for multicomponent behavioral intervention factorial trials in the multiphase optimization strategy framework: challenges and recommendations. 
  • Randomized clinical trials and common sense. 
  • Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or -unknown metastatic breast cancer: a Southeastern Cancer Study Group trial. 
  • Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. 
  • Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. 
  • Randomized trial of prostacyclin infusion in acute myocardial infarction. 
  • Randomized trial of web-based training about opioid therapy for chronic pain. 
  • Randomized trials of coronary artery bypass surgery: impact on clinical practice at Duke University Medical Center. 
  • Rapamycin for chemoprevention of upper aerodigestive tract cancers. 
  • Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. 
  • Rare PTCLs: treatment lagging behind pathobiologic advances. 
  • RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer. 
  • Rate control in patients with chronic atrial fibrillation. 
  • Rational approaches to the chemotherapy of medulloblastoma. 
  • Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes. 
  • Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction? 
  • Re-setting the biologic rationale for thermal therapy. 
  • Real-World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative. 
  • Reasons for nonenrollment in a clinical trial of acute lung injury. 
  • Reasons for optimism not disillusionment. 
  • Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. 
  • Recent Clinical Trials in Osteoporosis: A Firm Foundation or Falling Short? 
  • Recent advances in antifungal pharmacotherapy for invasive fungal infections. 
  • Recent advances in the search for a targeted immunomodulatory therapy for primary Sjögren's syndrome. 
  • Recent advances in the treatment of prostate cancer. 
  • Recent areas of development for dendritic cell vaccines. 
  • Recent developments in therapeutic cancer vaccines. 
  • Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate. 
  • Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. 
  • Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence. 
  • Recommendations for clinical trial evaluation of acute stroke therapies. 
  • Recommendations for data monitoring committees from the Clinical Trials Transformation Initiative. 
  • Recommendations for high-priority research on cancer-related fatigue in children and adults. 
  • Recommendations for myasthenia gravis clinical trials. 
  • Recommendations for national and local regulatory authorities concerning research in genetic markers of disease. 
  • Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. 
  • Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. 
  • Recommendations to Enhance Pediatric Cardiovascular Drug Development: Report of a Multi-Stakeholder Think Tank. 
  • Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. 
  • Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. 
  • Recommended patient-reported core set of symptoms to measure in head and neck cancer treatment trials. 
  • Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. 
  • Recruiting participants to cancer prevention clinical trials: lessons from successful community oncology networks. 
  • Recruitment and retention of pregnant women into clinical research trials: an overview of challenges, facilitators, and best practices. 
  • Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study. 
  • Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism. 
  • Redefining the role of biomarkers in heart failure trials: expert consensus document. 
  • Reduced REM latency predicts response to tricyclic medication in depressed outpatients. 
  • Reducing biochemical recurrence rates in EBRT-treated prostate cancer patients: the influence of dose and dose per fraction. 
  • Reduction in transplant-related complications in patients given intravenous immuno globulin after allogeneic marrow transplantation. 
  • Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. 
  • Reexamination of the Embolic Stroke of Undetermined Source Concept. 
  • Regional anaesthesia versus general anaesthesia, morbidity and mortality. 
  • Registration of clinical trials for publication. 
  • Regulatable aptamers in medicine: focus on antithrombotic strategies. 
  • Regulatory and ethical considerations for linking clinical and administrative databases. 
  • Relation of Norwood Shunt Type and Frequency of Arrhythmias at 6 Years (from the Single Ventricle Reconstruction Trial). 
  • Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). 
  • Relationship Between Longitudinal Coping Strategies and Outcomes in Patients With Acute Myeloid Leukemia. 
  • Relationship between antecedent angina pectoris and short-term prognosis after thrombolytic therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: A pooled analysis from four CALGB (alliance) clinical trials. 
  • Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. 
  • Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies. 
  • Release bias in accessing medical records in clinical trials: a STAR*D report. 
  • Relevance of the ADAM and UK Small Aneurysm trial data in the age of endovascular aneurysm repair. 
  • Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data. 
  • Repairing the broken market for antibiotic innovation. 
  • Reply to L.K. Mell et al. 
  • Reply to Phillips, Morris, and Walker. 
  • Reply: To PMID 22581550. 
  • Report by the ACNP Task Force on response and remission in major depressive disorder. 
  • Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: US Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD. 
  • Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. 
  • Report of the National Heart, Lung, and Blood Institute Working Group on Hypertension: Barriers to Translation. 
  • Report of the National Heart, Lung, and Blood Institute Working Group: An Integrated Network for Congenital Heart Disease Research. 
  • Reporting the findings of clinical trials: a discussion paper. 
  • Repositioning metformin for cancer prevention and treatment. 
  • Requiring 'independent' statistical analyses for industry sponsored trials? 
  • Research Participation of a Professional Organization in Clinical Trials: The Association of Black cardiologists Clinical Trial Investigator Identification Project. 
  • Research challenges in central nervous system manifestations of inborn errors of metabolism. 
  • Research design considerations for chronic pain prevention clinical trials: IMMPACT recommendations. 
  • Research design considerations for confirmatory chronic pain clinical trials: IMMPACT recommendations. 
  • Research misconduct and data fraud in clinical trials: prevalence and causal factors. 
  • Research on vaccines during pregnancy: protocol design and assessment of safety. 
  • Research priorities in cancer cachexia: The University of Rochester Cancer Center NCI Community Oncology Research Program Research Base Symposium on Cancer Cachexia and Sarcopenia. 
  • Research without borders: fostering innovative clinical research and implementation. 
  • Researching the world of children 
  • Respiratory Tract Infection Clinical Trials from 2007 to 2012. A Systematic Review of ClinicalTrials.gov. 
  • Respiratory controversies in the critical care setting. Does airway pressure release ventilation offer important new advantages in mechanical ventilator support? 
  • Respiratory therapies in the critical care setting. Should aerosolized antibiotics be administered to prevent or treat ventilator-associated pneumonia in patients who do not have cystic fibrosis? 
  • Response assessment criteria for brain metastases: proposal from the RANO group. 
  • Response characteristics to antidepressants and placebo in post-traumatic stress disorder. 
  • Response to "Global cardiovascular clinical trials and geographic altitude". 
  • Response to commentary on the multimodal treatment study of ADHD (MTA): mining the meaning of the MTA. 
  • Response to reader reaction. 
  • Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. 
  • Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. 
  • Results of recent large myocardial infarction trials, adjunctive therapies, and acute myocardial infarction: improving outcomes. 
  • Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray? 
  • Rethinking ovarian cancer: recommendations for improving outcomes. 
  • Review of advanced heart failure device diagnostics examined in clinical trials and the potential benefit from monitoring capabilities. 
  • Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder. 
  • Revisiting the Role of Aspirin for the Primary Prevention of Cardiovascular Disease. 
  • Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. 
  • Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme. 
  • Rising PSA in nonmetastatic prostate cancer. 
  • Rivaroxaban, an oral direct factor Xa inhibitor. 
  • Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. 
  • Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma. 
  • Role of Continuous Glucose Monitoring in Clinical Trials: Recommendations on Reporting. 
  • Role of cytokines in autologous bone marrow transplantation. 
  • Role of genetic polymorphisms in ovarian cancer susceptibility: development of an international ovarian cancer association consortium. 
  • Role of radiation therapy in patients with resectable pancreatic cancer. 
  • Roux-en-Y gastric bypass decreases serum inflammatory markers and cardiovascular risk factors in obese diabetics. 
  • Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. 
  • Ruboxistaurin. 
  • Ruxolitinib: a new treatment for myelofibrosis. 
  • SGO guidance document for clinical trial designs in ovarian cancer: a changing paradigm. 
  • SLC6A4 variation and citalopram response. 
  • SPIRIT 2013 Statement: defining standard protocol items for clinical trials. 
  • SPIRIT 2013 statement: defining standard protocol items for clinical trials. 
  • Safety and Efficacy of Exercise Training in Patients With an Implantable Cardioverter-Defibrillator: A Meta-Analysis. 
  • Safety and efficacy of pegfilgrastim in patients receiving myelosuppressive chemotherapy. 
  • Safety and patient acceptability of intravenous immune globulin in 10% maltose. 
  • Safety and technique of ferumoxytol administration for MRI. 
  • Safety and transparency of pediatric drug trials. 
  • Safety considerations with gastrointestinally active lipid-lowering drugs. 
  • Safety considerations with niacin therapy. 
  • Safety of transvenous cardiac resynchronization system implantation in patients with chronic heart failure: combined results of over 2,000 patients from a multicenter study program. 
  • Safety, dosing, and pharmaceutical quality for studies that evaluate medicinal products (including biological products) in neonates. 
  • Salivary gland malignancies: the role for chemotherapy and molecular targeted agents. 
  • Sample Size Requirements of Glaucoma Clinical Trials When Using Combined Optical Coherence Tomography and Visual Field Endpoints. 
  • Sample size calculations for clinical trials using the NIH Stroke Scale. 
  • Sample size computation for two-sample noninferiority log-rank test. 
  • Sample size determination based on rank tests in clinical trials. 
  • Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. 
  • Sample size re-estimation in clinical trials. 
  • Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected]. 
  • Science of Improvement Versus Science of Implementation: Integrating Both Into Clinical Inquiry. 
  • Scientific and clinical challenges in sepsis. 
  • Scientific and social issues of human immunodeficiency virus vaccine development. 
  • Scientific factors and current issues in biosimilar studies. 
  • Scientific, societal, and economic consequences of releasing interim data from clinical trials. 
  • Screening for lung cancer. 
  • Scrutinizing enrollment in ALS clinical trials: room for improvement? 
  • Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials. 
  • Secondary stroke prevention strategies for the oldest patients: possibilities and challenges. 
  • Seeking Similarities Rather Than Differences With Adults to Aid in Therapeutic Advancement for Children. 
  • Selecting factors predictive of heterogeneity in multivariate event time data. 
  • Selecting methodologies for the evaluation of differences in time to response between antidepressants. 
  • Selection of HIV vaccine candidates for concurrent testing in an efficacy trial. 
  • Selection of patients with melanoma brain metastases for aggressive treatment. 
  • Selective serotonin reuptake inhibitors in post-traumatic stress disorder. 
  • Semiparametric estimation of treatment effect in a pretest-posttest study. 
  • Sensible approaches for reducing clinical trial costs. 
  • Sequential clinical trials in cancer research. 
  • Serum Pepsinogen as a Biomarker for Gastric Cancer in the United States: A Nested Case-Control Study Using the PLCO Cancer Screening Trial Data. 
  • Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. 
  • Sex differences in incidence, pathophysiology, and outcome of primary intracerebral hemorrhage. 
  • Sexual function in women with urinary incontinence and pelvic organ prolapse. 
  • Sharing Data from Cardiovascular Clinical Trials--A Proposal. 
  • Shining More Light on RAS Inhibition during the COVID-19 Pandemic. 
  • Should academic medical centers conduct clinical trials of the efficacy of intercessory prayer? 
  • Should an institution that has commercial rights in a new drug or device be allowed to evaluate the technology? 
  • Should selective serotonin reuptake inhibitors be prescribed to all patients with ischemic heart disease? 
  • Silver bullets and structural impediments to HIV prevention. 
  • Simplifying informed consent for biorepositories: stakeholder perspectives. 
  • Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. 
  • Single versus multiple internal mammary artery grafting for coronary artery bypass: 15-year follow-up of a clinical practice trial. 
  • Single-dose versus multiple-dose piperacillin prophylaxis in primary cesarean operation. 
  • Site Principal Investigators in Multicenter Clinical Trials: Appropriately Recognizing Key Contributors. 
  • Site selection for heart failure clinical trials in the USA. 
  • Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. 
  • Skating to where the puck is going to be: a plan for clinical trials and translation research in mood disorders. 
  • Sleep Blood Pressure Self-Measured at Home as a Novel Determinant of Organ Damage: Japan Morning Surge Home Blood Pressure (J-HOP) Study. 
  • Small-cell lung cancer: a review of clinical trials. 
  • Small-molecule glycoprotein IIb/IIIa inhibitors as adjunctive therapy in percutaneous coronary interventions. 
  • Small-molecule nicotinamide for ex vivo expansion of umbilical cord blood. 
  • Smoothing spline-based score tests for proportional hazards models. 
  • Sodium and blood pressure: no data dredging, please! 
  • Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. 
  • Solvent-detergent-treated fresh frozen plasma: a superior alternative to standard fresh frozen plasma? 
  • Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). 
  • Special Issue of Journal of Biopharmaceutical Statistics dedicated to 2016 Trends and Innovations in Clinical Trial Statistics (TICTS) Conference. 
  • Special article: 2014 Pediatric Clinical Trials Forum. 
  • Staging techniques for lung cancer. 
  • Stakeholder acceptability of adolescent participation in clinical trials for biomedical HIV prevention products: considerations from Tanzania and India. 
  • Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. 
  • Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. 
  • Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. 
  • Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. 
  • Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. 
  • Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium. 
  • Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. 
  • State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach. 
  • State-of-the-Art Management of Hyperphosphatemia in Patients With CKD: An NKF-KDOQI Controversies Perspective. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. 
  • Statins after intracerebral hemorrhage: to treat or not to treat. 
  • Statins for stroke prevention. 
  • Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic. 
  • Statistical analysis for two-stage seamless design with different study endpoints. 
  • Statistical aspect of translational and correlative studies in clinical trials. 
  • Statistical consideration of adaptive methods in clinical development. 
  • Statistical considerations for analysis of microarray experiments. 
  • Statistical considerations for rare diseases drug development. 
  • Statistical inference for cancer trials with treatment switching. 
  • Statistical inference for clinical trials with binary responses when there is a shift in patient population. 
  • Statistical issues in quality-of-life assessment. 
  • Statistical issues in translational cancer research. 
  • Statistical issues on the diagnostic multivariate index assay for targeted clinical trials. 
  • Statistical methods for two-sequence three-period cross-over designs with incomplete data. 
  • Statistical methods in translational medicine. 
  • Statistical tests for one-way/two-way translation in translational medicine. 
  • Status of the pediatric clinical trials enterprise: an analysis of the US ClinicalTrials.gov registry. 
  • Stem Cell Therapy for Congenital Heart Disease: A Systematic Review. 
  • Stem Cells in Cardiovascular Diseases: 30,000-Foot View. 
  • Stereotactic radiotherapy for pancreatic cancer? 
  • Steroids for restenosis: strike three! 
  • Strategies for eliciting HIV-1 inhibitory antibodies. 
  • Strategies for research participant engagement: A synthetic review and conceptual framework. 
  • Strategies of patient care in acute coronary syndromes: rationale for the Global Registry of Acute Coronary Events (GRACE) registry. 
  • Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer. 
  • Stratified Fisher's exact test and its sample size calculation. 
  • Stroke and acute myocardial infarction in the thrombolytic era: clinical correlates and long-term prognosis. 
  • Stroke prevention in atrial fibrillation. 
  • Stroke recovery and rehabilitation. 
  • Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. 
  • Subgroups of failure after surgery for pelvic organ prolapse and associations with quality of life outcomes: a longitudinal cluster analysis. 
  • Substance use and schizophrenia: adverse correlates in the CATIE study sample. 
  • Suitability of Automated Writing Measures for Clinical Trial Outcome in Writer's Cramp. 
  • Summary of FDA antibody-mediated rejection workshop. 
  • Summary of the 44th Annual Meeting on Women's Cancers. 
  • Supporting open access to clinical trial data for researchers: The Duke Clinical Research Institute-Bristol-Myers Squibb Supporting Open Access to Researchers Initiative. 
  • Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. 
  • Surrogate markers in antiangiogenesis clinical trials. 
  • Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. 
  • Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. 
  • Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. 
  • Suspended judgment. Clinical trials of informed consent. 
  • Symptoms of interpersonal sensitivity in depression. 
  • Synthetic isoquinoline in acute respiratory disease. 
  • Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine initiative: clinical indicators. 
  • Systematic review and consensus definitions for the Standardized Endpoints in Perioperative Medicine (StEP) initiative: cardiovascular outcomes. 
  • Systematic review and metasummary of attitudes toward research in emergency medical conditions. 
  • Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. 
  • Systemic management of diabetic retinopathy. 
  • Systemic therapy for older women with breast cancer. 
  • Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). 
  • TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. 
  • Tackling Diversity in Prostate Cancer Clinical Trials: A Report From the Diversity Working Group of the IRONMAN Registry. 
  • Taking healthcare interventions from trial to practice. 
  • Targeted alpha-particle therapy of microscopic disease: Providing a further rationale for clinical investigation. 
  • Targeted delivery in primary and metastatic brain tumors: summary report of the seventh annual meeting of the Blood-Brain Barrier Disruption Consortium. 
  • Targeted inhibition of VEGF receptor 2: an update on ramucirumab. 
  • Targeted radiotherapy of brain tumours. 
  • Targeted therapy of colorectal cancer: clinical experience with bevacizumab. 
  • Targeting Isocitrate Dehydrogenase Mutations in Cancer: Emerging Evidence and Diverging Strategies. 
  • Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials. 
  • Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. 
  • Targeting Wnts at the source--new mechanisms, new biomarkers, new drugs. 
  • Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. 
  • Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. 
  • Task force 2: Investigator participation in clinical research. 
  • Technology evaluation: ISIS-2503, Isis Pharmaceuticals. 
  • Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb. 
  • Technology-Enabled Clinical Trials: Transforming Medical Evidence Generation. 
  • Tedizolid (TR-701): a new oxazolidinone with enhanced potency. 
  • Telavancin: a new lipoglycopeptide for gram-positive infections. 
  • Temozolomide in early stages of newly diagnosed malignant glioma and neoplastic meningitis. 
  • Temporal Trends and Clinical Trial Characteristics Associated With the Inclusion of Women in Heart Failure Trial Steering Committees: A Systematic Review. 
  • Temporal patterns of antihypertensive medication use among older adults, 1989 through 1992. An effect of the major clinical trials on clinical practice? 
  • Ten-Year Trends in Enrollment of Women and Minorities in Pivotal Trials Supporting Recent US Food and Drug Administration Approval of Novel Cardiometabolic Drugs. 
  • Testicular cancer survivorship: research strategies and recommendations. 
  • Testicular cancer. Clinical practice guidelines in oncology. 
  • Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. 
  • Testosterone supplementation for hypoactive sexual desire disorder in women. 
  • Tests for inter-subject and total variabilities under crossover designs. 
  • The 2009 Feinberg lecture: the continuum of stroke research and policy. 
  • The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. 
  • The Akt signaling pathway: an emerging therapeutic target in malignant melanoma. 
  • The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. 
  • The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. 
  • The Association of Previous Prostate Biopsy Related Complications and the Type of Complication with Patient Compliance with Rebiopsy Scheme. 
  • The Autism Biomarkers Consortium for Clinical Trials: Initial Evaluation of a Battery of Candidate EEG Biomarkers. 
  • The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. 
  • The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. 
  • The Center for HIV/AIDS Vaccine Immunology (CHAVI) multi-site quality assurance program for cryopreserved human peripheral blood mononuclear cells. 
  • The Child and Adolescent Psychiatry Trials Network (CAPTN). 
  • The China tuberculosis clinical trials consortium network: a model for international TB clinical trials capacity building. 
  • The Clinical Trials Transformation Initiative: Methodology supporting the mission. 
  • The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. 
  • The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay. 
  • The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? 
  • The Food and Drug Administration and pragmatic clinical trials of marketed medical products. 
  • The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. 
  • The Globalization of Heart Failure Research. 
  • The Immune Tolerance Network at 10 years: tolerance research at the bedside. 
  • The Immunology Quality Assessment Proficiency Testing Program for CD3⁺4⁺ and CD3⁺8⁺ lymphocyte subsets: a ten year review via longitudinal mixed effects modeling. 
  • The Impact of Worsening Heart Failure in the United States. 
  • The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma. 
  • The Landscape of Cardiovascular Clinical Trials in the United States Initiated Before and During COVID-19. 
  • The Landscape of Cell and Gene Therapies for Solid Tumors. 
  • The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. 
  • The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. 
  • The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. 
  • The Need for Pediatric Drug Development. 
  • The Ocular Hypertension Treatment Study: design and baseline description of the participants. 
  • The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients. 
  • The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5). 
  • The PROTEUS-Trials Consortium: Optimizing the use of patient-reported outcomes in clinical trials. 
  • The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. 
  • The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. 
  • The Rules of Engagement: CTTI Recommendations for Successful Collaborations Between Sponsors and Patient Groups Around Clinical Trials. 
  • The STAR*D study: treating depression in the real world. 
  • The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients. 
  • The Society for Clinical Trials supports United States legislation mandating trials registration. 
  • The Society of Thoracic Surgeons/American Association for Thoracic Surgery clinical practice guidelines on the management of type B aortic dissection. 
  • The Study of the Effects of Diet on Metabolism and Nutrition (STEDMAN) weight loss project: Rationale and design. 
  • The Tuskegee Legacy Project: history, preliminary scientific findings, and unanticipated societal benefits. 
  • The Tuskegee Legacy Project: willingness of minorities to participate in biomedical research. 
  • The audit process and how to ensure a successful audit. 
  • The best that surgery has to offer. 
  • The burden of proof: The current state of atrial fibrillation prevention and treatment trials. 
  • The calm after the cytokine storm: lessons from the TGN1412 trial. 
  • The cancer aging interface: a research agenda. 
  • The cancer and leukemia group B cancer in the elderly committee: addressing a major cancer need. 
  • The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: Pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). 
  • The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: Clinical trial evidence (acute coronary syndromes through renal disease) and future directions. 
  • The case against independent monitoring committees. 
  • The case for practical clinical trials in psychiatry. 
  • The changing perspective on chronic insomnia management. 
  • The chemoradiation paradigm in head and neck cancer. 
  • The clinical management of chondrosarcoma. 
  • The clinician as investigator: participating in clinical trials in the practice setting. 
  • The clinician as investigator: participating in clinical trials in the practice setting: Appendix 1: fundamentals of study design. 
  • The clinician as investigator: participating in clinical trials in the practice setting: Appendix 2: statistical concepts in study design and analysis. 
  • The concept and potentials of cardiovascular gene therapy. 
  • The concept of voluntary consent. 
  • The congestion score: a simple tool for a complicated disease? 
  • The convergence of cancer prevention and therapy in early-phase clinical drug development. 
  • The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. 
  • The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. 
  • The data center of the European Organization for Research on Treatment of Cancer. 
  • The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. 
  • The design and evaluation of HIV-1 vaccines. 
  • The design and implementation of an open-source, data-driven cohort recruitment system: the Duke Integrated Subject Cohort and Enrollment Research Network (DISCERN). 
  • The development of a decision analytic model of changes in mean deviation in people with glaucoma: the COA model. 
  • The double-blind in danger: untoward consequences of informed consent. 
  • The dual role of IL-10. 
  • The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. 
  • The economic returns of pediatric clinical trials of antihypertensive drugs. 
  • The effect of preoperative phenazopyridine on short-term urinary retention following urogynecologic surgery. 
  • The effect of timing of influenza vaccination and sample collection on antibody titers and responses in the aged. 
  • The effects of isocarboxazid on blood pressure and pulse. 
  • The emerging role of anti-angiogenic therapy for malignant glioma. 
  • The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. 
  • The endoscopic radiofrequency approach to management of GERD. 
  • The evolution and understanding of skeletal complication endpoints in clinical trials of tumors with metastasis to the bone. 
  • The evolving role of blood and marrow transplantation for the treatment of autoimmune diseases. 
  • The exclusion of women from clinical trials of thrombolytic therapy: implications for developing the thrombolytic predictive instrument database. 
  • The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. 
  • The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians. 
  • The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. 
  • The future of kidney cancer treatment. 
  • The glutamine story: where are we now? 
  • The immune response to HIV: implications for vaccine development. 
  • The impact of human immunodeficiency virus infection on drug-resistant tuberculosis. 
  • The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. 
  • The impact of surgery on ductal carcinoma in situ outcomes: the use of mastectomy. 
  • The impact of the international guideline entitled Statistical Principles for Clinical Trials (ICH E9). 
  • The implementation of the Fast Track program: an example of a large-scale prevention science efficacy trial. 
  • The implications of blood transfusions for patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE National Quality Improvement Initiative. 
  • The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. 
  • The importance of chemotherapy dose intensity in lung cancer. 
  • The incidence of venous thromboembolism in cancer patients: a real-world analysis. 
  • The influence of relationships on children's and adolescents' participation in research 
  • The landscape of clinical trials in nephrology: a systematic review of Clinicaltrials.gov. 
  • The long and winding road of the clinical development of Nelarabine. 
  • The long-term treatment of panic disorder. 
  • The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. 
  • The many meanings of care in clinical research. 
  • The modified Patient and Observer Scar Assessment Scale: a novel approach to defining pathologic and nonpathologic scarring. 
  • The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer. 
  • The national drug abuse treatment clinical trials network data share project: website design, usage, challenges, and future directions. 
  • The need for a re-evaluation of best supportive care studies reported to date. 
  • The need for inclusion of pregnant women in COVID-19 vaccine trials. 
  • The need for new clinical trials of old cardiovascular drugs. 
  • The need for wider utilization of thrombolytic therapy. 
  • The nonapproved use of medications. 
  • The once and future gene therapy. 
  • The past, present and future of renin-angiotensin aldosterone system inhibition. 
  • The perils of glaucoma surgical outcome analysis. 
  • The pharmacology of novel oral anticoagulants. 
  • The polypill to prevent cardiovascular disease: physicians' perspectives. 
  • The potential impact of nonpharmacologic population-wide blood pressure reduction on coronary heart disease events: pronounced benefits in African-Americans and hypertensives. 
  • The potential influence of Internet-based social networking on the conduct of clinical research studies. 
  • The potential of a placebo/nocebo effect in pharmacogenetics. 
  • The potential of monoclonal antibodies to reduce reperfusion injury in myocardial infarction. 
  • The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. 
  • The privacy rule (HIPAA) as it relates to clinical research. 
  • The radiosurgery fractionation quandary: single fraction or hypofractionation? 
  • The rationale for an acute heart failure syndromes clinical trials network. 
  • The rise of genomic profiling in ovarian cancer. 
  • The road to tolerance: renal transplant tolerance induction in nonhuman primate studies and clinical trials. 
  • The role of angioplasty after successful thrombolysis for acute myocardial infarction. 
  • The role of animal models in evaluating reasonable safety and efficacy for human trials of cell-based interventions for neurologic conditions. 
  • The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue? 
  • The role of arthroscopy in the treatment of lunotriquetral ligament injuries. 
  • The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials. 
  • The role of genetic and sociopolitical definitions of race in clinical trials. 
  • The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy. 
  • The role of isoflavones in menopausal health: consensus opinion of The North American Menopause Society. 
  • The role of local institutional review boards in protecting human research subjects. 
  • The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease. 
  • The role of surgery for patients with metastatic melanoma. 
  • The role of systemic hypertension in the progression of nondiabetic renal disease. 
  • The role of targeted therapy in the treatment of colorectal cancer. 
  • The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential. 
  • The role of the perfusion balloon catheter after an initially unsuccessful coronary intervention. 
  • The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. 
  • The sentinel node in colorectal carcinoma. Mapping technique, pathologic assessment, and clinical relevance. 
  • The state of infectious diseases clinical trials: a systematic review of ClinicalTrials.gov. 
  • The strengths and limitations of meta-analyses based on aggregate data. 
  • The surgeon and adjuvant therapy for stage II colon cancer. 
  • The surgical management of lung cancer. 
  • The top clinical trial opportunities in therapeutic apheresis and neurology. 
  • The topographic distribution of the first sites of diabetic retinal neovascularization. 
  • The treatment of primary insomnia. 
  • The unmet need for addressing cardiac issues in intensive care research. 
  • The use of high-fidelity human patient simulation as an evaluative tool in the development of clinical research protocols and procedures. 
  • The use of intraaortic balloon counterpulsation as an adjunct to reperfusion therapy in cardiogenic shock. 
  • The use of intraaortic balloon counterpulsation in acute myocardial infarction and high risk coronary angioplasty. 
  • The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. 
  • The use of multiattribute decision models in evaluating triptan treatment options in migraine. 
  • The use of placebos in unipolar major depression: the current status. 
  • The use of recombinant human granulocyte-macrophage colony-stimulating factor in autologous bone marrow transplantation. 
  • The utility of thermal dose as a predictor of tumor and normal tissue responses to combined radiation and hyperthermia. 
  • The validity and reliability of photographic documentation of proliferative vitreoretinopathy. 
  • The value of statistical analysis plans in observational research: defining high-quality research from the start. 
  • The year in Cardiothoracic and Vascular Anesthesia: selected highlights from 2014. 
  • Therapeutic Plasma Transfusion in Bleeding Patients: A Systematic Review. 
  • Therapeutic application of repetitive transcranial magnetic stimulation: a review. 
  • Therapeutic implications of biomarkers in chronic heart failure. 
  • Therapy and clinical trials. 
  • Therapy and clinical trials. 
  • Therapy and clinical trials. 
  • Therapy and clinical trials. 
  • Therapy and clinical trials. 
  • Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. 
  • Therapy for non-clear cell histologies in renal cancer. 
  • Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism. 
  • Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? 
  • Third universal definition of myocardial infarction. 
  • Third-party payers and investigational therapy. 
  • Three phylogenetic groups have driven the recent population expansion of Cryptococcus neoformans. 
  • Three- to four-year follow-up to an open trial of nefazodone for combat-related posttraumatic stress disorder. 
  • Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries Investigators. 
  • Thrombolytic Therapy for Acute Central Retinal Artery Occlusion. 
  • Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Ticagrelor for the treatment of arterial thrombosis. 
  • Tides of inflammation: impact of biologics. 
  • Time for NIH to lead on data sharing. 
  • Timely diagnosis of testicular cancer. 
  • Timing of surgery and radiotherapy in the management of metastatic spine disease: a systematic review. 
  • Tinkering and tailoring with HCV therapy: can we get away with less? 
  • Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea. 
  • Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. 
  • Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B. 
  • Topical microbicides: the time has come. 
  • Topical minoxidil in early male pattern baldness. 
  • Topical minoxidil in male pattern baldness: effects of discontinuation of treatment. 
  • Toward a Definition of "No Meaningful Benefit" From Antidepressant Treatment: An Equipercentile Analysis With Cross-Trial Validation Across Multiple Rating Scales. 
  • Toward a whole-body neuroprosthetic. 
  • Toward an Emerging Era of Optimization Research for Acupuncture. 
  • Toward evidence-based management of migraine. 
  • Toward protecting the safety of participants in clinical trials. 
  • Towards prevention of post-traumatic osteoarthritis: report from an international expert working group on considerations for the design and conduct of interventional studies following acute knee injury. 
  • Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. 
  • Toxin-based targeted therapy for malignant brain tumors. 
  • Tracheal gas insufflation: overcoming obstacles to clinical implementation. 
  • Transcatheter mitral valve repair for functional mitral regurgitation: Evaluating the evidence. 
  • Transcranial magnetic stimulation: applications in neuropsychiatry. 
  • Transcription factor decoy. 
  • Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group. 
  • Transient late magnetic resonance imaging changes suggesting progression of brain stem glioma: implications for entry criteria for phase II trials. 
  • Transition to chronic pain: opportunities for novel therapeutics. 
  • Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance. 
  • Translating clinical trials into clinical practice: a survey assessing the potential impact of the Pediatric Heart Network Infant Single Ventricle Trial. 
  • Translating evidence into practice: use of statins in real-world patients with heart failure. 
  • Translating genomic biomarkers into clinically useful diagnostics. 
  • Translational Research Working Group developmental pathway for immune response modifiers. 
  • Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? 
  • Transluminal extraction coronary atherectomy. 
  • Transmyocardial laser revascularization for inoperable coronary artery disease. 
  • Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6-7, 2011, Arlington, Virginia. 
  • Treating the enigmatic "exceptional responders" as patients with undiagnosed diseases. 
  • Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. 
  • Treatment of acute hepatitis C infection: more pieces of the puzzle? 
  • Treatment of bacterial prostatitis. Comparison of cephalexin and minocycline. 
  • Treatment of blepharitis: recent clinical trials. 
  • Treatment of childhood rhabdomyosarcoma at St. Jude Children's Research Hospital, 1962--78. 
  • Treatment of early rheumatoid arthritis. 
  • Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium. 
  • Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. 
  • Treatment of high-stage bladder cancer: case for adjunctive chemotherapy. 
  • Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. 
  • Treatment of hyperlipidemia with combined niacin-statin regimens. 
  • Treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. 
  • Treatment of infants with malignant gliomas: the Pediatric Oncology Group experience. 
  • Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy. 
  • Treatment of non-ST-elevation acute coronary syndrome in the elderly: current practice and future opportunities. 
  • Treatment of posttraumatic stress disorder with amitriptyline and placebo. 
  • Treatment of social phobia with benzodiazepines. 
  • Treatment options for newly diagnosed patients with chronic lymphocytic leukemia. 
  • Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. 
  • Treatment selection in metastatic renal cell carcinoma: more confusion or a path forward? 
  • Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion. 
  • Trends in Heart Failure Clinical Trials From 2001-2012. 
  • Trends in Performance of Anti-Incontinence Treatment at the Time of Pelvic Organ Prolapse Repair From 2011 to 2019. 
  • Trends in human immunodeficiency virus (HIV) counseling, testing, and antiretroviral treatment of HIV-infected women and perinatal transmission in North Carolina. 
  • Trends in prevalence of comorbidities in heart failure clinical trials. 
  • Trial Characteristics That Affect Parental Consent in Neonatal Drug Trials. 
  • Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel. 
  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 
  • Trial registration: ignored to irresistible. 
  • Trial summaries on results databases and journal publication. 
  • Trials in myocardial infarction. 
  • Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes. 
  • Troponin and other cardiac markers: role in management of acute coronary syndromes. 
  • Tumor acquisition for biomarker research in lung cancer. 
  • Tumor temperature distributions predict hyperthermia effect. 
  • Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. 
  • Tumour necrosis factor-alpha blockade: a new era for effective management of rheumatoid arthritis. 
  • Two-stage sampling in pharmaceutical applications. 
  • Tying clinical research to patient care by use of an observational database. 
  • Tyrosine kinase inhibitors in renal cell carcinoma. 
  • Umbilical cord blood transplantation for non-malignant diseases. 
  • Under-representation of women in high-impact published clinical cancer research. 
  • Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. 
  • Understanding the Cellular and Molecular Mechanisms of Physical Activity-Induced Health Benefits. 
  • Unintended changes in cognition, mood, and behavior arising from cell-based interventions for neurological conditions: ethical challenges. 
  • United States Thrombotic Thrombocytopenic Purpura Apheresis Study Group (US TTP ASG): multicenter survey and retrospective analysis of current efficacy of therapeutic plasma exchange. 
  • University of Pennsylvania 11th annual conference on statistical issues in clinical trials: Estimands, missing data and sensitivity analysis (morning panel session). 
  • Unmet Needs and Challenges in Clinical Research of Intracerebral Hemorrhage. 
  • Unpredictable drug shortages: an ethical framework for short-term rationing in hospitals. 
  • Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. 
  • Unravelling the smokers' paradox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y₁₂ inhibitors. 
  • Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. 
  • Update on magnetic seizure therapy: a novel form of convulsive therapy. 
  • Update on treatment advances in combined-modality therapy for anal and rectal carcinomas. 
  • Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. 
  • Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). 
  • Updating the 2003 European regulatory requirements for registering disease-modifying drugs to be used in the treatment of rheumatoid arthritis. 
  • Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. 
  • Urge overkill: protecting deidentified human subjects at what price? 
  • Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. 
  • Use of Open Access Platforms for Clinical Trial Data. 
  • Use of a new chemically modified intravenous IgG preparation in severe primary humoral immunodeficiency: clinical efficacy and attempts to individualize dosage. 
  • Use of altered informed consent in pragmatic clinical research. 
  • Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia. 
  • Use of barbiturate therapy in severe perinatal asphyxia: a randomized controlled trial. 
  • Use of bevacizumab in recurrent glioblastoma. 
  • Use of bupropion in combination with serotonin reuptake inhibitors. 
  • Use of glycoprotein IIb/IIIa inhibition plus fibrinolysis in acute myocardial infarction. 
  • Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. 
  • Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. 
  • Use of outcome measures in pulmonary hypertension clinical trials. 
  • Use of research biopsies in clinical trials: are risks and benefits adequately discussed? 
  • Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee. 
  • Use of thymic grafts or thymic factors to augment immunologic recovery after bone marrow transplantation: brief report with 2 to 12 years' follow-up. 
  • User-centered design principles in the development of clinical research tools. 
  • Using ClinicalTrials.gov to understand the state of clinical research in pulmonary, critical care, and sleep medicine. 
  • Using Cognitive Interviews to Enhance Measurement in Empirical Bioethics: Developing a Measure of the Preventive Misconception in Biomedical HIV Prevention Trials. 
  • Using Digital Health Technology to Better Generate Evidence and Deliver Evidence-Based Care. 
  • Using Medical Informatics to Improve Clinical Trial Operations. 
  • Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. 
  • Using a latent variable approach to inform gender and racial/ethnic differences in cocaine dependence: a National Drug Abuse Treatment Clinical Trials Network study. 
  • Using central IRBs for multicenter clinical trials in the United States. 
  • Using clinical trial summary results to establish quality measures [4] 
  • Using decision lists to construct interpretable and parsimonious treatment regimes. 
  • Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). 
  • Using item banks to construct measures of patient reported outcomes in clinical trials: investigator perceptions. 
  • Utility of Patient-Reported Outcome Instruments in Heart Failure. 
  • Utilizing propensity scores to estimate causal treatment effects with censored time-lagged data. 
  • Vaccination against herpes zoster in developed countries: state of the evidence. 
  • Vaccine therapy in non-small-cell lung cancer. 
  • Vagus nerve stimulation in depression. 
  • Validation of eye-tracking measures of social attention as a potential biomarker for autism clinical trials. 
  • Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. 
  • Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. 
  • Vascular renin-angiotensin system and vascular protection. 
  • Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin. 
  • Vasodilator therapy in acute myocardial infarction. A comparison of sodium nitroprusside and nitroglycerin. 
  • Vasopressin receptor antagonists. 
  • Venous thromboembolism in cancer clinical trials: recommendation for standardized reporting and analysis. 
  • Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid. 
  • Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope. 
  • Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. 
  • Vorapaxar in the secondary prevention of atherothrombosis. 
  • Vorapaxar: a novel protease-activated receptor-1 inhibitor. 
  • WITHDRAWN: Antibiotics for acute maxillary sinusitis in adults. 
  • We need further studies for the development of "optimized antiplatelet therapy" based on ethnicity. 
  • Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Science Advisory From the American Heart Association. 
  • Wearable Devices in Clinical Trials: Hype and Hypothesis. 
  • Web-based communications and management of a multi-center clinical trial: the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project. 
  • Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. 
  • Weight reduction at the work site: a promise partially fulfilled. 
  • Weighted likelihood method for grouped survival data in case-cohort studies with application to HIV vaccine trials. 
  • Weighting composite endpoints in clinical trials: essential evidence for the heart team. 
  • What can we learn from a decade of database audits? The Duke Clinical Research Institute experience, 1997--2006. 
  • What constitutes clinical evidence for neuroprotection in Alzheimer disease: support for the cholinesterase inhibitors? 
  • What is sufficient evidence for the reliability and validity of patient-reported outcome measures? 
  • What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? 
  • What's next in the pipeline. 
  • When Should Patients Be Involved in Cardiovascular Clinical Trial Design?: Always, Early, and Often. 
  • When is an adjuvant not an adjuvant? Overview. 
  • Where We Stand With Immunotherapy in Colorectal Cancer: Deficient Mismatch Repair, Proficient Mismatch Repair, and Toxicity Management. 
  • Which depressions respond to placebo? 
  • Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? 
  • White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. 
  • Who refuses enrollment in cardiac clinical trials? 
  • Who should go first in trials with scarce agents? The views of potential participants. 
  • Whole-genome sequencing of Staphylococcus epidermidis bloodstream isolates from a prospective clinical trial reveals that complicated bacteraemia is caused by a limited number of closely related sequence types. 
  • Why Negative Trials Are Positive for Heart Failure Patients. 
  • Why Should We Publish All Clinical Trials? 
  • Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand. 
  • Willingness to participate in clinical trials among patients of Chinese heritage: a meta-synthesis. 
  • Wnt Signaling and Drug Resistance in Cancer. 
  • Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. 
  • Women's views about participating in research while pregnant. 
  • Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. 
  • [Calcium antagonists in the treatment of heart failure. Re-evaluation of therapeutic strategies]. 
  • [Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]. 
  • alpha-Interferon and 5-fluorouracil: possible mechanisms of antitumor action. 
  • eSource-Enabled vs. Traditional Clinical Trial Data Collection Methods: A Site-Level Economic Analysis. 
  • gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. 
  • rHuEPO and improved treatment outcomes: potential modes of action. 
  • rTMS strategies for the study and treatment of schizophrenia: a review. 
  • {I}ndependent but coordinated trials: insights from the practice-based {O}pportunities for {W}eight {R}eduction {T}rials {C}ollaborative {R}esearch {G}roup 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Allen, Nancy Bates, Professor Emeritus of Medicine, Medicine, Rheumatology and Immunology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Berger, Miles, Associate Professor of Anesthesiology, Duke Science & Society
  • Bitting, Rhonda L, Associate Professor of Medicine, Medicine, Medical Oncology
  • Chanti-Ketterl, Marianne, Assistant Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences
  • Cohen-Wolkowiez, Michael, Kiser-Arena Distinguished Professor, Pediatrics, Infectious Diseases
  • Cotten, Charles Michael, Professor of Pediatrics, Pediatrics, Neonatology
  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • Grambow, Steven C., Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Hirschey, Matthew, Associate Professor of Medicine, Cell Biology
  • LeBlanc, Thomas William, Associate Professor of Medicine, Duke Cancer Institute
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • Limkakeng Jr., Alexander Tan, Professor of Emergency Medicine, Emergency Medicine
  • Lo, Joseph Yuan-Chieh, Professor in Radiology, Electrical and Computer Engineering
  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • Milano, Carmelo Alessio, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • Myers, Evan Robert, Walter L. Thomas Distinguished Professor of Obstetrics and Gynecology in the School of Medicine, Duke Cancer Institute
  • Nieuwsma, Jason A, Associate Professor in Psychiatry and Behavioral Sciences, Psychiatry & Behavioral Sciences, Behavioral Medicine & Neurosciences
  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Olson, Steven Arthur, Goldner Jones Distinguished Professor of Orthopaedic Surgery, Orthopaedic Surgery
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patel, Uptal Dinesh, Adjunct Professor in the Department of Medicine, Medicine, Nephrology
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Shinohara, Mari L., Professor of Integrative Immunobiology, Cell Biology
  • Sreenivasan, Gopal, Crown University Distinguished Professor in Ethics, Duke Science & Society
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Taekman, Jeffrey Marc, Professor Emeritus of Anesthesiology, Anesthesiology, Neuroanesthesia
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine
  • Yancy Jr., William Samuel, Professor of Medicine, Medicine, General Internal Medicine
  • Zafar, Syed Yousuf, Adjunct Professor in the Department of Medicine, Duke Science & Society